

Accepted Manuscript

Hot Topic

Depression in Cancer: the many biobehavioural pathways driving tumor progression

Beatrice Bortolato, Thomas N. Hyphantis, Sara Valpione, Giulia Perini, Michael Maes, Gerwyn Morris, Marta Kubera, Cristiano A. Köhler, Brisa S. Fernandes, Brendon Stubbs, Nicholas Pavlidis, André F. Carvalho


PII: S0305-7372(16)30120-7
DOI: <http://dx.doi.org/10.1016/j.ctrv.2016.11.004>
Reference: YCTRV 1569

To appear in: *Cancer Treatment Reviews Cancer Treatment Reviews*

Received Date: 12 April 2016
Revised Date: 15 October 2016
Accepted Date: 5 November 2016

Please cite this article as: Bortolato, B., Hyphantis, T.N., Valpione, S., Perini, G., Maes, M., Morris, G., Kubera, M., Köhler, C.A., Fernandes, B.S., Stubbs, B., Pavlidis, N., Carvalho, A.F., Depression in Cancer: the many biobehavioural pathways driving tumor progression, *Cancer Treatment Reviews Cancer Treatment Reviews* (2016), doi: <http://dx.doi.org/10.1016/j.ctrv.2016.11.004>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



Depression in Cancer: the many biobehavioural pathways driving tumor progression

Authors: Beatrice Bortolato¹, Thomas N. Hyphantis², Sara Valpione³, Giulia Perini⁴, Michael Maes^{5,6,7,8,9}, Gerwyn Morris¹⁰, Marta Kubera¹¹, Cristiano A. Köhler¹², Brisa S. Fernandes^{13,14}, Brendon Stubbs^{15,16,17}, Nicholas Pavlidis¹⁸, André F. Carvalho¹²

¹Department of Mental Health ULSS 10 “Veneto Orientale”, Venice, Italy

²Department of Psychiatry, Division of Medicine, School of Health Sciences, University of Ioannina, Greece

³Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy; Medical Oncology; The Christie NHS Trust, Manchester, United Kingdom

⁴Department of Neurosciences, University of Padova, Padova, Italy

⁵IMPACT Strategic Research Centre, Deakin University, School of Medicine and Barwon Health, Geelong, VIC, Australia

⁶Department of Psychiatry, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand

⁷Department of Psychiatry, Faculty of Medicine, State University of Londrina, Londrina, Brazil

⁸Department of Psychiatry, Medical University Plovdiv, Plovdiv, Bulgaria

⁹Revitalis, Waalre, the Netherlands

¹⁰Tir Na Nog, Bryn Road seaside 87, Llanelli, SA152LW, Wales, UK

¹¹Department of Experimental Neuroendocrinology, Institute of Pharmacology, Polish Academy of Science, Krakow, Poland

¹²Department of Clinical Medicine and Translational Psychiatry Research Group, Faculty of Medicine, Fortaleza, CE, Brazil

¹³Deakin University, IMPACT Strategic Research Centre, School of Medicine, and Barwon Health, Geelong, Australia.

¹⁴Laboratory of Calcium Binding Proteins in the Central Nervous System, Department of Biochemistry, Federal University of Rio Grande do Sul, Porto Alegre, Brazil

¹⁵Physiotherapy Department, South London and Maudsley NHS Foundation Trust, Denmark Hill, London SE5 8AZ, United Kingdom

¹⁶Health Service and Population Research Department, Institute of Psychiatry, Psychology and Neuroscience, King's College London, De Crespigny Park, London, Box SE5 8AF, United Kingdom

¹⁷Faculty of Health, Social care and Education, Anglia Ruskin University, Bishop Hall Lane, Chelmsford CM1 1SQ, United Kingdom

¹⁸Department of Medical Oncology, Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, 45110, Greece

Corresponding author: André F. Carvalho, MD, PhD; Department of Clinical Medicine, Faculty of Medicine, Federal University of Ceará, Rua Prof. Costa Mendes, 1608, 4o andar, 60430-040, Fortaleza, CE, Brazil. Phone/Fax: +55 85 33668054. E-mail: andrefc7@terra.com.br

Abstract

Major Depressive Disorder (MDD) is common among cancer patients, with prevalence rates up to four-times higher than the general population. Depression confers worse outcomes, including non-adherence to treatment and increased mortality in the oncology setting. Advances in the understanding of neurobiological underpinnings of depression have revealed shared biobehavioral mechanisms may contribute to cancer progression. Moreover, psychosocial stressors in cancer promote: (1) inflammation and oxidative/nitrosative stress; (2) a decreased immunosurveillance; and (3) a dysfunctional activation of the autonomic nervous system and of the hypothalamic-pituitary-adrenal axis. Consequently, the prompt recognition of depression among patients with cancer who may benefit of treatment strategies targeting depressive symptoms, cognitive dysfunction, fatigue and sleep disturbances, is a public health priority. Moreover, behavioral strategies aiming at reducing psychological distress and depressive symptoms, including addressing unhealthy diet and life-style choices, as well as physical inactivity and sleep dysfunction, may represent important strategies not only to treat depression, but also to improve wider cancer-related outcomes. Herein, we provide a comprehensive review of the intertwined biobehavioural pathways linking depression to cancer progression. In addition, the clinical implications of these findings are critically reviewed.

Keywords: major depressive disorder, cancer, inflammation, HPA axis, stress, psychiatry

Highlights:

- Depression is highly prevalent among individuals with cancer
- Co-morbid depression may lead to a worse prognosis among cancer patients
- Preclinical and clinical evidence instantiate the role of inflammation and oxidative and nitrosative stress in the pathophysiology both of cancer and depression
- Psychosocial stressors in cancer promote inflammation, a dysregulated activation of the hypothalamic-pituitary-adrenal axis and reduced immunosurveillance
- Behavioral strategies may target biological mechanisms relevant to tumor progression and depressive clinical manifestations

ACCEPTED MANUSCRIPT

Introduction

Major Depressive Disorder (MDD) is more common among individuals affected by cancer as compared to the general population. While the average rate of MDD is 3.3% in the general population, the prevalence of MDD among individuals with cancer is approximately 12.5%, which is up to four-times the rate reported in population-based samples ¹. Evidence indicates that co-morbid depression may be associated with a worse prognosis and increased mortality rate in cancer populations ². In fact, depression is an independent predictor of more frequent and longer hospitalizations, diminished quality of life and decreased compliance to treatments ³. Meta-analytic evidence indicates that depression triples the risk for non-adherence to medications in women with breast cancer ⁴. Moreover, demotivation may promote maladaptive depressive coping styles with a detrimental effect on survival ⁵ as well as potentially increase suicidal risk ⁶. Notwithstanding depression is under-recognized in cancer population, limited evidence provides support for the routine screening of distress in cancer populations ⁷. Importantly, the treatment of depression has been associated with increased survival in women with metastatic cancer ⁸. Furthermore, interventions aiming at improving depression management, education and behavioral activation (*i.e.* emphasizing pleasant event scheduling and overcoming avoidance behaviors), along with the use of antidepressant treatments when appropriate, have been recognized as effective in reducing depressive burden in individuals with cancer ⁹.

Notwithstanding the burgeoning and stressful potential associated with a diagnosis of cancer, the large prevalence of depression among individuals with cancer is likely to not be entirely explained by the effects of psychological distress. In recent years, advances in the neurobiology of depression and in the physiopathology of cancer have led to the identification of some shared bio-behavioral mechanisms ¹⁰⁻¹⁴. This field

has witnessed an ever increasing accumulation of emerging findings, which deserve a critical review.

Therefore, this comprehensive narrative review aims to: 1) explore epidemiological links between depression and cancer progression; 2) summarize biological mechanisms relevant for the development and recurrence of depressive episodes as well as for cancer progression, with potential mutual reciprocal interactions; and 3) describe behavioral interventions that may target mechanistic pathways relevant to both depression and cancer progression.

Search Strategy

A comprehensive search for peer-reviewed articles published in English was performed in the PubMed/Medline database including the following search terms: “Major Depressive Disorder”, “cancer”, “tumor”, “inflammation”, “oxidative and nitrosative stress”, “HPA axis”, “diet”, “microbiota”, “physical exercise”, “sleep dysfunction” up until February 15th, 2016. Bibliographies from selected articles were reviewed to identify additional original reports aligned with our objectives.

Epidemiological links between depression and cancer

Most studies report that the prevalence of depression in oncological populations range from 15% to 30%, with variations attributable to different screening tools and diagnostic criteria across studies ¹⁵. These heterogeneous results are in part explainable by the fact that only a limited number of studies have assessed the prevalence of depression in cancer samples used a structured diagnostic interview according to criteria established in the Diagnostic and Statistical Manual of Mental Disorders (DSM) or the International Classification of Diseases (ICD). On the contrary, it is noteworthy that self-rated reports of depression or the detection of

depressive symptoms by clinicians do not substantiate a reliable diagnosis of MDD. In keeping with this view, it is not surprising that the prevalence of individuals meeting a diagnosis of MDD according to a structured clinical interview is relatively lower compared to the prevalence of depressive symptoms among individuals with cancer¹⁶. Meta-analytic evidence of 24 studies involving 4007 subjects from palliative-care settings documented a prevalence of MDD as defined according to the DSM-IV of 16.5% (95% CI 13.1–20.3), while the prevalence of all types of depression was 20.7% (12.9–29.8) and that of minor depression of 9.6% (3.6–18.1)¹⁷. A recent meta-analysis examining the role of depression as a putative risk of cancer have been recently conducted¹⁸. This meta-analysis of nine observational studies demonstrated that a DSM or ICD diagnosis of depression was not conclusively associated with cancer risk. In addition, there was a lack of well-designed prospective cohort studies examining this association¹⁸.

Depressive symptoms typically develop during the first year after cancer diagnosis and usually decline as a result of adaptive adjustments to psychological stress related to the diagnosis¹⁹. For instance, in an epidemiological survey exploring the prevalence of depressive symptoms among subjects of five biennial waves of the Health and Retirement Study, involving 8,387 individuals aged 51-61, subjects diagnosed with cancer had the highest hazard ratio of depressive symptoms within 2 years following initial diagnosis (HR 3.55; 95%, CI, 2.79-4.52), when compared to individuals diagnosed with diabetes, hypertension, heart disease, arthritis, chronic lung disease or stroke²⁰. The chances of developing a new depressive episode following a diagnosis of cancer may be elevated in certain vulnerable groups (e.g., those patients with a previous history of depressive episodes), as suggested by an observational study exploring the relationship between acute stress disorder and

subsequent depressive symptoms after a diagnosis of head/neck/lung cancer²¹. In this study up to 29% of individuals met the criteria for MDD within the first month after the diagnosis, of whom nearly one-third had a positive history for previous depressive episodes²¹.

There is also some accumulating evidence indicating that affective and somatic depressive symptoms may occur prior to the establishment of a cancer diagnosis^{22,23}.

For instance, a previous study among people with a new diagnosis of pancreatic cancer, found that affective symptoms were evident several months before the cancer diagnosis in addition to somatic symptoms including fatigue, anorexia, and insomnia²⁴. Somatic symptoms are extremely common among populations with different types of cancer and may potentially be an expression of both depression and/ or the underlying neoplasm²⁵. However, in spite of the fact that fatigue and weight loss/gain are more frequently reported by women with ovarian cancer during advanced (stages III–IV) versus early (stages I–II) stages, the onset of these symptoms may begin up to 2–7 months prior to diagnosis, suggesting that these manifestations may result from shared mechanisms that also drive tumorigenesis²⁶. Furthermore, in women awaiting surgery for suspected ovarian cancer, depressive symptoms have been reported more frequently in those receiving a subsequent diagnosis of cancer compared to those with tumors of low malignant potential²⁷. Similarly, depressive symptoms have been documented in up to approximately 30% of women before the diagnosis of breast cancer²⁸. However, other studies have provided contrasting results and have not reported a significant difference in depressive symptom severity in women with a subsequent diagnosis of breast cancer as compared to women with a benign breast disease²⁹. Lastly, it should be noted that cancer treatment may also contribute to the development of depressive symptoms. Immune-inflammatory and O&NS alterations

following chemotherapy may be partially responsible for the worsening and/or the initiation of somatic and affective symptoms of depression, including fatigue, sleep dysfunction and cognitive complaints³⁰.

The role of stress and inflammation

Tumorigenesis and cancer progression are characterized by the acquisition of six biological attributes, representing the “hallmarks of cancer” namely (1) resisting cell death; (2) sustaining proliferative signaling; (3) evading growth suppressors; (4) inducing angiogenesis (5) resisting cell death; and (6) activating invasion and metastasis³¹. Continued oxidative stress can propitiate chronic inflammation, which may influence cancer progression. Hence, oxidative stress can activate transcription factors and lead to the expression of over 500 different genes, including those related to growth factors, pro-inflammatory cytokines, chemokines, cell-cycle regulatory molecules, and anti-inflammatory molecules, suggesting that oxidative stress, chronic inflammation, and cancer are closely intertwined³².

Host factors, including cell-mediated immunity, are involved in surveillance and destruction of tumor cells, especially in early disease stages. Stress-induced processes can directly modulate these tumor hallmarks and a large body of preclinical and clinical evidence supports the role of inflammation as an essential factor for tumor growth and progression¹. Pro-inflammatory cytokines are produced by tumor and stromal cells, as well as by tumor-associated macrophages and infiltrating T-cells, and play an important role in tumor angiogenesis, metastatic spread, and possibly resistance to therapy^{22, 33}. In addition, stress-related effects on angiogenesis may be regulated by neural control mechanisms. In particular, stressors promote angiogenesis via enhanced adrenergic transmission, which stimulate the production of cytokines

(*e.g.*, IL 6, IL-8, TNF- α) and vascular endothelial growth factor (VEGF) by the activation of cognate beta-adrenergic receptors on tumor and stromal cells ³⁴. Furthermore, stress-induced activation of the sympathetic nervous system promotes metastatic invasion via an increase in the expression of enzymes endowed with the ability of destroying the cellular matrix surrounding the tumor, *e.g.* matrix metalloproteinases (MMP) 2 and MMP-9, which are produced by both tumor cells and macrophages in the tumor microenvironment and may be regulated by stress-triggered factors ³⁵. On the contrary, the activation of the parasympathetic nervous system appears to down-regulate the immune response and dampen the production of pro-inflammatory cytokines, through cholinergic-mediated decrease in the expression of nuclear factor kappa B (NF- κ B), an effect referred to as the “cholinergic anti-inflammatory pathway” ³⁶.

The production of cytokines in the periphery leads to an amplification of the pro-inflammatory response at the central nervous system (CNS) via an increase in the permeability of the blood-brain barrier (BBB) on circumventricular organs and in the choroid plexus, or via afferent vagal fibers innervating the nucleus of the solitary tract ³⁷. In addition, growing evidence indicates that perivascular monocytes may infiltrate the brain, promoting the spread of inflammatory stimuli to microglia and astrocytes, which in turn become the main source of immune-inflammatory mediators within the brain ³⁸. A large body of preclinical and clinical data indicates that an increase in pro-inflammatory cytokines are associated with the so-called “sickness syndrome”, whose manifestations include anhedonia, irritability, psychomotor retardation, fatigue, anorexia, insomnia, and increased pain sensitivity ³⁹. Those symptoms overlap to some extent with the clinical manifestations of depression and are partly responsive to antidepressant treatments. Thus, the immune cross-talk between the central nervous

system (CSM) and the periphery is thought to be largely responsible for the development of somatic and affective symptoms of depression under pro-inflammatory conditions, while also possibly contributing to carcinogenesis⁴⁰.

Inflammatory aberrations associated with depression

Literature supporting the role of inflammation in depression is extensive. Increased expression of innate immune mediators, including cytokines and acute phase reactants, chemokines and soluble receptor molecules are among the most replicated findings not only in peripheral blood but in the cerebrospinal fluid (CSF) or in post-mortem brain samples of suicide victims⁴¹. For instance, some meta-analyses have documented higher peripheral levels of pro-inflammatory cytokines namely IL-6, IL-8, IL-1 β , TNF- α , soluble IL-2 receptor (sIL-2R) and C-reactive protein (CRP) in individuals with MDD when compared to healthy controls^{42, 43}. Conversely, in longitudinal population studies, higher CRP levels have been demonstrated to predispose individuals in developing subsequent depressive symptoms, thus supporting that the notion that the activation of the immune system may contribute to the patho-etiology of depression⁴⁴. Further support to this idea derives from evidence that the administration of interferon alpha (IFN)- α to patients with cancer is associated with the development of depressive symptoms, that only partially respond to conventional antidepressant treatments⁴⁵. Polymorphisms in inflammatory cytokine genes, including those encoding for IL-1 β , TNF- α and CRP, have also been related to antidepressant treatment response⁴⁶.

In addition to evidence instantiating the role of innate immunity in the pathophysiology of depression, other lines of research focused on alterations in adaptive cellular immunity⁴⁷. In fact, increased levels of pro-inflammatory cytokines

and reduced signaling of anti-inflammatory mediators, such as IL-10 and transforming growth factor beta (TGF- β), may direct the differentiation of T naïve cells towards the T helper 1 (Th1)/Th17 phenotype instead of T regulatory (T reg) cells, further promoting the production of pro-inflammatory mediators (e.g., IFN, IL-2) in a vicious circle^{48,49}. Pro-inflammatory cytokines stimulate the activation of the enzyme indoleamine 2-3 dioxygenase (IDO), which converts tryptophan into kynurenine (KYN), leading to serotonin deprivation⁵⁰. In microglial cells, KYN may be further converted into quinolinic acid (QUIN), a powerful N-methyl-D-aspartate (NMDA) agonist and stimulator of glutamate release. QUIN and other tryptophan catabolites induce the further production of pro-inflammatory cytokines and potentiate oxidative and nitrosative stress provoking lipid peroxidation, mitochondrial dysfunction and DNA damage⁵¹. In this context, it is noteworthy to highlight that recent research also pointed to a role of IDO in the control of inflammation and in peripheral immune-tolerance in cancer patients⁵². In fact, IDO activation can be triggered by innate responses during tumorigenesis, and also by T cell activation, thus representing a potential target for immunotherapy.

Finally, cascades associated with the activation of the aforementioned pathways appear to lead to excitotoxic neural damage, a reduced expression of brain derived neurotrophic factor (BDNF) and consequently to a disruption of mechanisms subserving neural plasticity^{53,54}. In addition, oxidative stress may reduce the activity of 5,6,7,8-tetrahydrobiopterin (BH4), which is a co-factor for several aromatic amino acid monooxygenases and is rate-limiting for the biosynthesis of the neurotransmitter serotonin and the catecholamines dopamine, epinephrine and norepinephrine⁵⁵. Thus, the reduced biosynthesis of catecholamines may also be related to disturbed adrenergic neurotransmitter pathways under chronic low-grade inflammatory states.

During the last decade, the hypothesis of a pro-inflammatory imbalance implicated in the pathophysiology of depression has gained momentum, and provided the rationale for testing putative antidepressant properties of several non-steroidal anti-inflammatory drugs and cytokine inhibitors⁵⁶. Of note, anti-inflammatory treatments may represent useful treatment options in particular for a subset of individuals with MDD exhibiting low-grade chronic activation of pro-inflammatory pathways. For instance, treatment with the TNF antagonist infliximab was effective in reducing depressive symptoms in individuals with treatment-resistant MDD showing baseline CRP levels > 3 mg/dl⁵⁷. In this study, treatment response was associated with transcriptional signatures related to glucose and lipid metabolism⁵⁸. Maladaptive habits, including unhealthy diet and smoking, as well as environmental factors, including childhood abuse, have been consistently associated with pro-inflammatory activation⁵⁹. For instance, individuals with a history of childhood abuse exhibit higher plasma CRP, IL-6 and TNF- α levels during adulthood in comparison to healthy controls⁶⁰ and are exposed to greater risk of chronic diseases in adulthood including cancer, depression, cardiovascular disease and metabolic syndrome⁶¹. Consequently, the characterization of a subset of MDD subjects more marked disruption of pro-inflammatory pathways has emerged as a relevant priority in this field of research.

Immune activation and alterations in stress response in depression associated with cancer

The presence of comorbid depression has been demonstrated to have a negative prognostic impact across different cancer populations. For instance, depression has been associated with shorter survival in patients with renal carcinoma⁶². Of note, a

subgroup analysis revealed that increased gene expression related to inflammatory pathways and oxidative stress as well as greater activity of the nuclear transcriptional factor NF- κ B in circulating leucocytes, were positively associated with depressive symptoms' severity⁶². In keeping with this view, elevated concentrations of cytokines (e.g., IL-6 and TNF- α) have been associated with later cancer stages, poor differentiation and tumor size/volume across a variety of malignancies. Therefore, the detrimental prognostic impact of depression in comorbidity with cancer may be at least in part mediated by the activation inflammatory cascades²². For example, increased plasma levels of IL-6 were observed in association with depressive symptoms in individuals with advanced ovarian cancer as compared to subjects with tumors of low-grade malignant potential²⁷. Similarly, IL-6 levels have been associated with depressive symptoms in individuals with cancer¹⁰. In addition, increased plasma levels of the IL-1 receptor antagonist and soluble TNF receptor 2 (sTNFR2) correlated with fatigue in breast cancer survivors up to 5 years after the diagnosis⁶³. Lastly, the blockade of cytokines' signaling has been associated with reductions in depressive symptoms and better quality of life in patients with advanced cancer⁶⁴.

Unsurprisingly, abnormalities in the stress responses appear to be closely linked to the immune activation. For instance, pro-inflammatory activation is highly associated with hypothalamic–pituitary–adrenal (HPA) axis dysfunction, notably higher evening cortisol levels²⁷. A dysregulated pattern of cortisol secretion has been consistently associated with depression and fatigue in cancer patients⁶⁵. Elevated nocturnal cortisol levels and a flattened diurnal cortisol slope have been observed in individuals with breast, ovarian, cervical cancer and lymphoma, and may predict poor survival⁶⁶. These abnormalities in cortisol secretion appear to stimulate the growth and survival

of cancer cells, leading cancer treatment resistance and inhibiting apoptosis of tumor cells⁶⁷. Moreover, glucocorticoids negatively influence DNA repair and modulate genetic transcriptional activities⁶⁸.

The treatment of cancer may in part mitigate pro-inflammatory aberrations and the dysfunctional activation of the HPA axis. For instance, surgical treatment followed by chemotherapy in high-risk ovarian cancer patients was found to be effective in reducing IL-6 levels and nocturnal cortisol and in improving neurovegetative symptoms of depression, fatigue and quality of life⁶⁹. However, other lines of evidence indicate that cancer treatments may induce *per se* inflammatory pathways relevant to the development of depressive symptoms. For instance, chemotherapy has been associated with an increase in the activity of NF- κ B as well as an increase in levels of IL-6 and sTNFR2 in parallel to increases in depressive symptoms in women with breast cancer⁷⁰.

Further support to the involvement of inflammation in the development of cancer-associated depression derives from the evidence that subjects with cancer receiving IFN treatment have a greater likelihood to exhibit depressive symptoms. Up to 50% of individuals with melanoma treated with IFN develop a variety of neurobehavioural symptoms including psychomotor retardation, anorexia, insomnia, and fatigue⁷¹. The presence of depressive symptoms prior to IFN treatment has been recognized as one of the most robust predictors of depression, and is may be an exclusion criterion for IFN therapy because of the substantial risk of depression⁷².

Use of antidepressants and cancer

The use of antidepressant treatment is associated with reductions in depressive symptoms across cancer samples, as documented by several randomized controlled

trials (RCTs) utilizing mianserin ⁷³, serotonin reuptake inhibitors (SSRIs; e.g. fluoxetine and paroxetine) ⁷¹ as well as tricyclic antidepressants (TCAs; e.g. amitriptyline and desipramine) ⁷⁴. In addition, some antidepressants (e.g. mirtazapine) may also alleviate chemotherapy-induced nausea and cancer-related cachexia-anorexia ^{75, 76}. Prophylactic treatment with paroxetine was effective in reducing depressive symptoms after IFN treatment ⁷¹. Therefore, the assessment of depressive symptoms among individuals with cancer prior to treatment initiation may aid in the identification of vulnerable subjects for whom prophylactic antidepressant treatment may be indicated. However, since only up to 30% of individuals with MDD achieve symptomatic remission following a trial with a first-line antidepressant treatment ⁷⁷, the identification of novel alternative or complementary treatment strategies is a priority for improving outcomes of depressed individuals suffering from cancer.

On the other hand, several clinical and experimental studies have suggested a link between antidepressant use and cancer ⁷⁸. Epidemiological studies on the effects of antidepressants on cancer prognosis suggest that the long-term use of TCAs and SSRIs may increase the risk of breast ^{79, 80} and ovarian cancer ⁸¹, whereas the use of TCAs may increase risk of prostate cancer and non-Hodgkin's lymphoma ⁸². However, several further studies did not find a significant association between antidepressant treatment and risk towards breast and ovarian cancers ⁸³, and non-Hodgkin's lymphoma ⁸⁴. Moreover, regular use of SSRIs may reduce risk of colorectal ⁸⁵ and lung ⁸⁶ cancers.

Whereas epidemiological studies concentrated on the association between antidepressant drugs and cancer incidence, animal models of cancer have been used to delineate the effects of antidepressant drugs on cancer progression ⁸⁷. Thus, fluoxetine

administration after B16F10 melanoma cells injection dramatically inhibited solid tumor growth⁸⁸, whereas chronic pretreatment with fluoxetine or desipramine before melanoma cells inoculation dramatically promoted metastasis formation and increased mortality rate in highly active young male and female animals by impairing the efficiency of anti-tumor immunity and enhancing the implantation efficiency of melanoma cells^{89, 90}. Kubera *et al.* (2011) reported a decreased production of Th1 cytokines and increased IL-10/IFN-gamma ratio in high-active C57BL/6J mice pretreated with desipramine (males) and fluoxetine (females) before injection of melanoma cells (decreasing antitumor immunity). The mechanism of metastatic promotion by the pretreatment with antidepressant drugs before the inoculation of tumor cells deserve further examination, and may have relevant clinical implications. For example, cancer patients taking antidepressants before surgical manipulation may show an increased risk of cancer cell dissemination during surgery⁹⁰, although further studies are required to fully appreciate the benefits and harms of antidepressant use in individuals with malignancies.

Effects of oxidative and nitrosative stress (O&NS)

Chronic inflammation characterised by elevated levels of pro-inflammatory cytokines leads to activation of inducible nitric oxide synthase (iNOS) and increased activity of several transcription factors, such as NF- κ B (nuclear factor κ B), AP-1 (activator protein 1) and STAT3 (signal transducer and activator of transcription 3) leading in turn to upregulated activity of NADPH oxidase (NOX) and mitochondrial oxidoreductases⁹¹. The activation of these enzymes and transcription factors lead to the chronic activation of a wide range of inflammatory pathways subsequent to the up-regulation of COX-2 (cyclo-oxygenase-2), and the development of a state of

chronic O&NS characterised by excessive production of reactive oxygen species (ROS), such as the superoxide anion, and reactive nitrogen species (RNS), such as nitric oxide (NO), which are known to play a major role in the pathogenesis and pathophysiology of major depression and inflammatory cancers ⁹².

There is now evidence that depression is accompanied by an increase in O&NS as indicated by an increase in lipid peroxidation, oxidative and nitrosative damage to DNA, nitrosative damage to proteins, hypernitrosylation, autoimmune responses to oxidatively and nitrosatively modified epitopes (neoepitopes, including malondialdehyde (MDA), oxidized LDL and NO-adducts ^{93, 94}. These activated O&NS pathways are partly related to lowered levels of key antioxidants including lowered levels of coenzyme Q10, zinc, vitamin E, glutathione, HDL-cholesterol, albumin, etc. ⁹³. Both the activated O&NS pathways and lowered levels of key antioxidants may be associated with different symptom profiles, the specific neurotransmitter pathophysiology of depression and staging of depression including chronicity of depression (e.g. increased autoimmune responses to neoepitopes) and treatment resistance (e.g. lowered coenzyme Q10 and zinc) ⁹³. In addition, increased ROS, RNS, lipid peroxidation, and lowered levels of antioxidants such as zinc and coenzyme Q10 aggravate existing inflammatory responses, and may cause autoimmune responses leading to more inflammation and cause chronic inflammatory responses ⁹³. Another dimension of pathology involves the consequences of hypernitrosylation, that is increased nitrosylation of cysteine groups in selected proteins by nitric oxide (NO) ⁹³. There is some evidence that abnormal levels of this post transcriptional modification may underpin the degenerative processes including neurodegeneration, abnormal hippocampal long-term potentiation, impaired synaptogenesis, neuronal survival ^{93, 94}.

An abundant amount of evidence has illustrated that activated O&NS pathways play a role in the pathophysiology and maybe the onset of specific cancers. Firstly, elevated levels of ROS and RNS, in an environment of compromised cellular antioxidant defences, may damage DNA, lipids and proteins and may lead to DNA mutations⁹². Such macromolecular damage leads to compromised protein functions, mitochondrial impairment, compromised cell membrane integrity, genetic instability and the formation of damage associated molecular patterns whose engagement with pattern recognition receptors can create a cascade of self-amplifying immune-inflammatory and O&NS pathology as detected in different cancers⁹⁵. ROS signalling plays a major role in the regulation of metabolism, cell fate, tumour cell proliferation, angiogenesis, and metastasis. A second dimension of pathology involves the consequences of abnormal nitrosylation of cysteine groups in selected proteins by NO⁹⁶. S-nitrosylation is now recognised as a major vehicle enabling the regulation of redox based protein signal transduction by NO in a cellular environment^{97, 98} and its dysregulation can produce a plethora of pathogenic consequences in several disease areas, including cancer⁹⁹. A state of hypernitrosylation caused by excessive levels of NO and dysregulated S-nitrosylation are implicated in the genesis and progression of cancer as well as treatment resistance¹⁰⁰. For example, tumour growth is regulated by S-nitrosylation of Ras and the epidermal growth factor receptor¹⁰¹. Cellular migration and cancer invasiveness may be enhanced by nitrosylation on the integrin alpha chain and nitrosylation of c-Src¹⁰² in prostate and breast cancers. Dysregulated S-nitrosylation also seems to explain, at least in part, the Janus faced role of NO in cancer whereby the molecule exerts pro-tumorigenic or anti-tumorigenic effects depending on cellular context and concentration. The weight of evidence indicates that moderately elevated levels of protein nitrosylation stimulate the development and

progression of cancers while excessive levels provoke the activation of enzyme signalling cascades such as the Ras/Erk/MAP kinase pathway leading to cellular apoptosis¹⁰³.

Stress as a modulator of immune response in depression and cancer

Psychosocial stressors including low perceived social support, lack of familiar ties as well as history of childhood trauma and adverse life experiences appear to increase the susceptibility to chronic diseases, including MDD and cancer¹⁰⁴. Moreover, chronic psychosocial stress increases cancer mortality across a diverse array of cancer types (e.g., breast, lung, head and neck, hepatobiliary, lymphoid, and hematopoietic cancers)^{105, 106}. A possible behavioral explanation implies the fact that psychological stress exerts detrimental effects on sleep architecture integrity and increases fatigue. In addition, increased threat perception may promote unhealthy lifestyle choices including dietary habits, smoking and alcohol abuse, and lack of physical activity. Furthermore, stressors may be responsible for cognitive complaints, especially in the domain of memory, which could have a role in diminishing treatment compliance¹⁰⁷.

However, at a mechanistic level, mounting evidence indicates that chronic stress confer increased vulnerability to chronic diseases amplifying pro-inflammatory signals via an increased production of cytokines and other immune mediators, as well as via a decreased sensitivity to hormonal inhibitory control by the HPA axis, as well altered autonomic responses^{108, 109}. Moreover, a pro-inflammatory milieu promotes oxidative and nitrosative stress that may promote mitochondrial dysfunction and DNA damage¹¹⁰. This view is supported by evidence indicating that stressful experiences increase immune responses even in healthy individuals. For instance, the exposure to the Trier Social Stress Test (TSST), a test including tasks of mental

arithmetic and public speaking, has been associated with activation of NF- κ B in peripheral blood mononuclear cells ¹¹¹. However, individuals with MDD with early life stress exhibit an exaggerated pro-inflammatory activation in comparison to healthy individuals to psychosocial stressors ¹¹².

In subjects with cancer, stress appears to influence every phase of tumor progression, from cancer initiation to angiogenesis promotion and metastatic spread ¹¹³. A large body of preclinical data indicates that stress promotes inflammatory dysregulation and affect immune response in cancer models of depressive-like behavior ²². These data were also confirmed in clinical settings. For instance, lower social support predicted greater VEGF gene expression and higher IL-6 levels in individuals with colon and ovarian cancer respectively, suggesting enhanced angiogenic potential ^{114, 115}. Moreover, low subjective social support has been associated with elevated intratumoral levels of norepinephrine in patients with ovarian cancer, thus instantiating the role of beta-adrenergic signaling on tumor growth control ¹¹⁶. Similarly, stress-induced autonomic response via beta-adrenergic transmission is associated with increased invasive potential through increased expression in MMPs ³⁴. Moreover, stress promotes tumor cells resistance to programmed cell death in the pro-inflammatory tumor microenvironment ¹¹⁷. Lastly, beta-adrenergic effects induce the loss of phagocytic abilities by tumor-associated macrophages and promote the propagation of the inflammatory response ³⁵.

High levels of psychological distress and low social support predict not only impaired activity of the immune innate system, but worse immune cellular response as well. In individuals with stage II and III breast cancer before a surgery intervention, high stress levels as assessed with a self-reported questionnaire (i.e., Impact of Event

Scale) predicted subsequent reduced lysis potential by natural killer (NK) cells, as well as diminished response of NK cells to IFN gamma and decreased proliferative response of peripheral blood lymphocytes to a monoclonal antibody stimulating the T-cell receptor¹¹⁸. A subsequent small follow-up study involving a subset of patients demonstrated that dysfunctional alterations in NK-cells activity in association with high levels of psychological stress may be long-lasting, although the relevance of stress-induced detrimental effects on cancer survival and recurrence is still unclear¹¹⁹.

At a molecular level, epigenetic mechanisms have been posited to underlie many of the associations between environmental stress exposure and dysfunctional endocrine and immune response through its long-lasting impact on gene expression. The most studied epigenetic modifications include changes in the methylation of cytosine-guanine dinucleotides (CpGs), but include as well histone modifications, silencing of the extra copy of the X-chromosome in females, genomic imprinting and alterations in non-coding RNA¹²⁰. Life adversities may influence molecular pathways relevant to the HPA-axis signaling and immune activation, leading to long-lasting immunological and endocrine dysfunction, which confers increased vulnerability to the subsequent development of depression and inflammatory diseases¹²¹.

For instance, early life adversities have been associated with increased cytosine methylation in the exon 1F of the neuron-specific glucocorticoid receptor (NR3C1) promoter, which leads to reduced hippocampal NR3C1 gene expression¹²². Lower glucocorticoid receptor (GR) activity is related to the hyper-activation of the HPA axis. In keeping with this, another study showed that male victims of suicide with history of childhood adversities exhibit increased methylation in the promoter of the *NR3C1* gene as compared to male victims without history of adversity, thus

supporting the idea that stress-induced epigenetic control of the GR expression is relevant to the pathophysiology of MDD¹²³.

Moreover, childhood trauma-dependent DNA demethylation in the FK-506 binding protein 5 (FKBP5) gene, which codes for a heat shock protein (HSP)-90 co-chaperone, has been linked to increased risk of developing psychiatric disorders in adulthood¹²⁴. In fact, when FKBP5 binds HSP-90, the complex decreases GR affinity to cortisol and prevents GR translocation to the cell nucleus and the consequent promotion of target genes transcription. Thus, as a result of stress-induced increased demethylation, the subsequent up-regulation of FKBP5 contributes to reduced GR sensitivity¹²⁵. Another candidate that has been repeatedly investigated for early stress-induced epigenetic changes in depression is the *BDNF* gene. Increased methylation of the promoter in the *BDNF* gene has been associated with reduced gene transcription and associated to increased suicidality among individuals with MDD¹²⁶. However, preliminary evidence indicates that changes in the methylation of the promoter of *BDNF* gene may occur only during the transition from adolescence to adulthood, suggesting the complexity of gene versus environment interactions in shaping developmental trajectories¹²⁷.

Stress, gut dysbiosis, and the “leaky gut”

During the first weeks of life, the gut is progressively colonized by a variety of symbionts, which are important for digestion and a relevant source of nutrients. The most common bacterial phyla present in the gut include the *Firmicutes*, *Bacteroidetes*, *Actinobacteria*, and *Proteobacteria*¹²⁸. The composition of microbiota is highly sensitive to the impact of chronic stress¹²⁹. A growing body of evidence indicates that the development of the CNS and of the HPA axis is highly influenced by alterations

in microbiota composition. For example, early stress in the perinatal period, including maternal separation, exerts a huge impact on the microbiota translating into long-lasting immunological aberrations¹³⁰. Immune challenges in mice during pregnancy, induced with the administration of lipopolysaccharide or with direct injection of IL-6, are associated with increased gut permeability and increased IL-6 expression in the colonic epithelium of the off springs¹³¹. Preclinical studies demonstrated that the absence of microbiota in germ-free animals is associated with behavioral abnormalities, altered gene expression in several brain areas, as well as with an increased turnover of key neurotransmitters, which may persist into adulthood¹³². Under chronic stressful conditions and also MDD, commensal bacteria and microbial-associated molecular patterns in the gut can leak into the peripheral circulation and activate the inflammasome, a cytosolic protein complex that lead to the amplification of pro-inflammatory responses via increased production of cytokines and other immune mediators^{133, 134}. Thus, major depression is accompanied by increased bacterial translocation of gram negative bacteria, such as *Hafnia alvei*, *Pseudomonas aeruginosa*, *Morganella morganii*, *Pseudomonas putida*, *Citrobacter koseri*, and *Klebsiella pneumonia* as indicated by increased IgM and IgA responses to the LPS of these commensal gut bacteria^{135, 136}. Moreover, this increased bacterial translocation in depression is associated with increased inflammatory responses, but especially with activated O&NS pathways, including lipid peroxidation and hypernitrosylation, and autoimmune responses to oxidative and nitrosative specific neoepitopes¹³⁷. In addition, in another disease strongly comorbid with depression, i.e. chronic fatigue syndrome, highly significant correlations were found between increased bacterial translocation through increased gut permeability (leaky gut) and increased levels of pro-inflammatory cytokines and autoimmune responses directed against serotonin¹³⁶,

137.

Therefore, increased bacterial translocation of gram negative bacteria following leaky gut play an important role in the amplification of pro-inflammatory and O&NS signals and Toll-like receptor (TLR) activation and thus the maintenance of chronic activation of immune-inflammatory pathways⁹⁵.

Several studies suggest that microbiota dysbiosis also plays a pivotal role also in cancer, influencing the dynamic control of gene expression and immunosurveillance¹³⁸. The production by the microbiota of several low-molecular weight bioactive substances, including folate, butyrate, biotin and acetate is involved in the regulation of DNA expression, replication and repair, while also enabling immune-tolerance¹³⁸. These dynamic processes may be critical during early stages of carcinogenesis, as well as in more advanced phases related to tumor progression. For instance, folate is a vitamin acting as a carbon-unit acceptor, involved in several metabolic pathways, including the biosynthesis of nucleotides and amino acids¹³⁹. Its availability largely influences DNA replication, repair and methylation. Butyrate is a short-chain fatty acid, mostly produced by the *Firmicute* bacteria phyla, that has been shown to play a role in tumorigenesis by promoting the expression of epigenetically silenced genes through the inhibition of histone deacetylase¹⁴⁰. In addition, it enhances the production of pro-angiogenic factors driving tumor progression¹⁴¹. Biotin is a vitamin not constitutively produced by humans and supplied by intestinal microbiota. Biotinylation of histone proteins is an important epigenetic process resulting in gene repression and relevant to DNA repair processes¹⁴². Butyrate and acetate, which are fermentation products from dietary fibers metabolized by gut microbiota exert anti-inflammatory activity and regulate the infiltration of macrophages¹⁴³. Thus,

alterations in the microbiome induce pro-inflammatory responses that may contribute to tumor initiation and development¹⁴⁴. Moreover, gut microbiota is a major donor of acetyl groups in histone acetylation reactions, which is an epigenetic regulatory mechanism influencing gene expression at the chromatin level¹⁴⁵. Since oncogenes' signaling during carcinogenesis may affect acetylation processes and thus chromatin remodeling, gut microbiota manipulations with dietary strategies in cancer studies may increase the armamentarium of available treatment options. Interestingly, the modulation of microbiota composition via dietary intervention has recently emerged as a promising strategy for the treatment of major mental disorders, including depression^{146, 147}.

The impact of behavioral strategies on depression associated with cancer

Effects of Psychological treatments on depression in patients with cancer

Recent results support the hypothesis that a variety of psychological interventions may be effective in promoting resilience to stress and reinforcing social support, including standard cognitive behavioral therapy and mindfulness-based therapy, but also multimodal approaches including psychoeducational interventions, anticipatory guidance and measures of psychosocial support¹⁴⁸. As recently reviewed elsewhere extensively¹, the majority of RCTs were performed on subjects suffering from breast cancer, while literature exploring the impact of psychological treatments in other types of cancer is relatively scarce, albeit rapidly growing. However, despite the scarceness of confirmatory studies, there is a large evidence supporting a model in which behavioral interventions may promote biological effects, with a positive impact on the innate and cellular immune response and in the modulation of the HPA axis activity. For instance, psychological treatment was effective in increasing the host T

cell response as well as enhancing the cytotoxicity of NK cells ^{149, 150}. Significant increases in the percentage of large granular lymphocytes and NK cytotoxic activity and a small decrease in the percentage of TH CD4+ cells were observed following a 6-week psychiatric group intervention for patients with malignant melanoma, and correlated with improvements in the affective symptoms' severity ¹⁵¹. Reductions in cortisol levels or normalization of diurnal cortisol patterns have also been reported ^{150, 152}. The changes in immunological and endocrine responses associated with psychological interventions do not seem only to exert a beneficial impact on coping strategies, stress relieving, affective symptoms and on quality of life measures ¹⁵³⁻¹⁵⁵, but there is also some evidence of a long-lasting effect on survival. For instance, in a study with a 11-year follow-up of breast cancer patients, psychological treatment was effective in reducing the risk of recurrence (hazard ratio [HR]= 0.55; 95% CI 0.28-0.93) and death from breast cancer (HR = 0.44; 95% CI 0.32-0.957) ¹⁵⁶. In addition, among those patients exhibiting a recurrence, a decreased risk of death was reported in the intervention arm as compared to controls (HR = 0.41; 95% CI 0.20–0.83) ¹⁵⁷. Therefore, enhancing positive psychological resources through dedicated programs can be considered an adjunctive useful strategy in developing intervention protocols for decreasing depressive symptoms, and may improve survival through the amelioration of shared pathways involved in both the pathophysiology of depression and cancer survival.

The influence of diet on tumorigenesis and depression

The potential of some dietary strategies in influencing biological pathways relevant to carcinogenesis is well supported by epidemiological data instantiating that diet enriched with fruits and vegetables may confer protection from the development of cancer (e.g., colorectal cancer)¹⁵⁸. In contrast, a diet enriched with refined grains has been associated with higher risk of colorectal cancer¹⁵⁹, as well as with a lowered cancer survival¹⁶⁰. Conversely, the supplementation with omega-3-fatty acids with 2 g/day of fish oil for the first 9 week of chemotherapy was effective in contributing to delaying tumor progression and increasing survival in subjects with colorectal cancer¹⁶¹. At a mechanistic level, omega-3-fatty acids appear to trigger apoptosis of colon cancer cells through a mitochondrial pathway¹⁶². Furthermore, some of these beneficial effects of omega-3 fatty acids may be mediated by alteration in the gut microbiota¹⁶³.

Cruciferous vegetables such as cabbage, broccoli, kale, and cauliflower are rich sources of fiber, lutein, flavonoids, phytosterols, folic acid, sulfur-containing glucosinolates and vitamin C, each of which has been associated with reduced risk of various kinds of cancer¹⁶⁴. In contrast, high dietary consumption of fat and processed red meat is associated with increased risk of cancer, possibly via increased activity of N-nitroso compounds and heterocyclic aromatic amines¹⁶⁵. In fact, gut microbiota appears to be pivotal mediators in the production of nitrosative reactive species from red meat consumption. The production of DNA-damaging nitrosative and oxidative reactive species by gut commensals has been posited to further increase the risk of cancer¹⁶⁶. Diet composition appears to influence as well metabolic pathways under hormonal control, for example in estrogen-driven breast, ovarian and endometrial cancers. The conversion of potentially genotoxic estrogens to their inactive

metabolites is mediated by hepatic conjugation via catechol-O-methyltransferase (COMT). The consumption of a diet enriched with vegetables (e.g., tomatoes), natural source of COMT, may thus exert a protective effect reducing the exposure to estrogens ¹⁶⁷.

Similarly, convergent data indicate that a diet enriched with the aforementioned elements may also exert a protective effect against the development of depressive symptoms. In fact, the most replicated clinical data informing on dietary recommendations for the prevention of depression indicates the benefits of increased consumption of fruit, vegetables, legumes, whole-grain cereals, nuts and seeds, fish rich in omega-3 polyunsaturated fatty acids as well as the limitation of the intake of processed-foods, 'fast' foods and commercial bakery goods ¹⁶⁸. The following of traditional diets mainly composed with the above-mentioned healthy products, including the Mediterranean, Norwegian or Japanese diet, has been associated with decreased inflammation associated with cardiovascular disease and metabolic syndrome ¹⁶⁹. In addition, the Mediterranean diet has been associated with improvements in depressive symptoms as well ¹⁷⁰. Taken together these data indicate that behavioral interventions including dietary changes may serve as useful strategies to prevent the development of depressive symptoms. In addition, maladaptive dietetic and non-dietetic habits appear to modify the susceptibility to associated comorbidities and to worsen the prognostic outcome of cancer, thus representing a target for behavioral adjunctive treatment strategies. For instance, smoking has been associated with a high risk of recurrence in oropharynx cancer ¹⁷¹, as well as with lower adherence to treatments in breast cancer ¹⁷². Moreover, results of a recent meta-analysis indicate that smoking increases the risk of recurrence of urothelial carcinoma

(HR=1.27, 95% C.I. = 1.09-1.46) and worsen prognostic outcome with decreased survival (HR=1.23, 95% C.I. = 1.02-1.44)¹⁷³. Schoenfeld and Ioannidis¹⁷⁴ selected 50 ingredients from random recipes in a cookbook, and reviewed observational studies and meta-analyses performed for each ingredient. The authors found that although 40 (80%) ingredients had articles assessing their association with cancer risk, the epidemiological credibility of those associations was limited, and effect size estimates of relative risks (RR) from meta-analyses were on average null.

The involvement of cancer patients in programs aiming at improving dietary education and promoting healthy lifestyle choices as a complementary treatment strategy may offer alternative opportunities to target both tumor progression and depressive symptoms.

Physical activity

Individuals with cancer are often affected by fatigue, which can also predate the clinical diagnosis and persist for several years. Fatigue significantly limits quality of life, reduces psychosocial functioning and is an independent predictor of decreased survival in individuals with terminal disease¹⁷⁵. Recent advances in the neurobiology of fatigue revealed that it is more likely to be related to biological pathways promoting neuroinflammation than with primary alterations involving the muscles¹⁷⁶. For instance, animal rat models of cancer-induced fatigue suggested that behavioral alterations occur in parallel with the increased expression of IL-1 β mRNA in the cortex and the hippocampus¹⁷⁶.

Exercise plays a vital role in improving physical fitness in cancer survivors¹⁷⁷. Moreover, physical activity should be considered as a key factor of lifestyle

interventions also to reverse negative treatment-related side effects¹⁷⁸. Since physical exercise has been recognized as a powerful modulator of neuroplasticity and immune response with immunosurveillance-enhancing properties¹⁷⁹, recent investigations started to increasingly explore the potential of additional exercise programs to usual treatment in improving psychosocial functioning as well as fatigue, cognitive functioning and depressive symptoms in individuals with cancer^{180, 181}. For instance, a small RCT on individuals with colorectal cancer undergoing chemotherapy documented that an adjunctive 18-week supervised exercise program improved fatigue, as assessed by the Multidimensional Fatigue Inventory (MFI) and the Fatigue Quality List (FQL), as well as physical functioning as compared to usual treatment¹⁸². Similarly, a 12-week exercise program, utilizing a combination of aerobic and resistance exercise, demonstrated improved measures of fatigue in patients with haematological cancers¹⁸³. Another RCT on patients with prostate cancer undergoing a 12-week exercise program, comprising two supervised gym session and one home-based session per week, documented a beneficial impact on depressive symptoms as assessed by the 20-item Center for Epidemiological Studies Depression Inventory (Cohen's $d = -0.35$; 95% CI, -0.71 to 0.02)¹⁸⁴. In keeping with this view, in another RCT on patients with lung cancer, an adjunctive 12-week exercise intervention, consisting in moderate-intensity walking for 40 min per day, 3 days per week, was feasible and effective in reducing depressive symptoms and anxiety as assessed by the Hospital Anxiety and Depression Scale (HADS)¹⁸⁵. Another RCT, examining the differential impact between a high-intensity and a low-moderate regimen of physical exercise in subjects with cancer, demonstrated that both regimens are effective in reducing measures of fatigue and physical functioning as compared to wait-list controls¹⁸⁶. Moreover, physical exercise programs improved measures of work

functioning. In keeping with this view, a program of low-to-moderate intensity exercise was effective in improving fatigue, quality of life and depression in women with ovarian cancer ¹⁸⁷.

Classical yoga programs combining warming, postures and breathing exercises with relaxation are currently studied for their potentially beneficial impact on depressive symptoms, pain perception and fatigue in women with breast cancer ¹⁸⁸. Similarly, an additional yoga program to usual treatment (e.g., surgery followed by adjuvant radiotherapy or chemotherapy) provided significant improvements in depressive symptoms' severity on the Beck's Depression Inventory as compared to supportive therapy in a RCT involving patients with stage II and III breast cancer ¹⁸⁹. However, other RCTs did not confirm these data ¹⁹⁰. For instance, a 8-week yoga exercise program with twice-per-week sessions was effective in reducing fatigue in patients with non-metastatic breast cancer undergoing adjuvant chemotherapy but did not reduce depressive symptoms ¹⁹¹.

Preliminary data instantiate also the potential of exercise programs in reversing at least in part some pro-inflammatory alterations associated with specific treatments in patients with cancer. For instance, in a RCT examining the effect of physical exercise on fatigue and on the levels of inflammatory markers in patients with breast cancer following radiation therapy, a program of progressive resistance exercise was effective in counteracting the increase in IL-6 levels and IL 6/IL-1RA ratio associated with radiation therapy ¹⁹². The impact of physical exercise on fatigue was partially attributable to the reduction in the levels of inflammatory markers. Moreover, physical exercise interventions exert regulatory effects on the HPA axis activity, with important implications for stress resilience. For instance, a 6-month a combined

program including exercise and hypocaloric diet in women with breast cancer was effective in reducing depressive symptoms on the BDI-II, which was associated to a normalisation of HPA axis regulation, as indicated by an increase in morning salivary cortisol at the 6-month follow-up in the intervention group as compared to controls¹⁹³.

There is robust evidence from the non-cancer literature that physical activity is effective for reducing depression, including those with MDD¹⁹⁴. A recent systematic review indicates that these beneficial effects may be partly mediated by a decrease in oxidative stress and (neuro) inflammation, although the evidence remains limited¹⁹⁵.

Taken together, these data indicate that physical exercise is a useful complementary intervention with potential beneficial effects on psychological stress, depression and fatigue among people with cancer. Further trials with larger samples and longer follow-up periods are warranted to evaluate the effects of exercise intervention for people suffering from different malignancies. Furthermore, trials with overall survival as the primary outcome are needed to determine whether the suggested benefits will translate into a survival advantage.

Sleep dysfunction as a target in cancer-related depression

The prevalence of poor sleep quality is common among cancer populations, affecting up to 50% of cancer survivors and being 2-fold or 3-fold that of general community¹⁹⁶. Sleep dysfunction consists of delayed sleep latency, waking episodes after sleep onset and reduced quality of sleep¹⁹⁷. Notwithstanding sleep disorders are acknowledged as predisposing risk factors for cancer development, their prevalence appear to rise during the course of the disease¹⁹⁷. Separate studies have documented

that sleep dysfunction usually occurs throughout the disease trajectory and is highly associated with psychological distress, fatigue and depression¹⁹⁸. For instance, in patients with cervical cancer before and after adjuvant therapy, poor sleep quality, as assessed by the Pittsburgh Sleep Quality Index, was significantly associated with depression, as assessed by the HADS and fatigue, as assessed by the MFI¹⁹⁸. Moreover, in this study, cancer treatments, including chemotherapy and possibly glucocorticoids and antiemetics significantly contributed to sleep problems, playing a major role in worsening sleep quality. In keeping with this view, in women with breast cancer receiving adjuvant treatment with tamoxifen, the duration of the chemotherapy treatment was significantly associated with the progressive increment of the number of awakenings and sleep disturbances¹⁹⁹.

Notwithstanding these data suggest that the incidence of sleep dysfunction contributes to the severity of depression and fatigue in cancer populations, the direction of causality is highly debated to date, since other data demonstrated that sleep dysfunction is a strong predictor of relapse in MDD and a less powerful predictor of incident MDD in community-based populations^{200, 201}.

Sleep architecture exerts deep influences on the modulation of the immune system's activity. Sleep dysfunction and sleep deprivation result in an activation of pro-inflammatory response with increased blood levels of IL-6²⁰². Additionally, sleep loss is associated with the upregulation of leukocyte expression of pro-inflammatory cytokine genes and increased NF-kB activity²⁰³. Additionally, sleep disturbances appear to be associated also with a disrupted cortisol rhythm. For instance, in women with breast cancer, sleep disturbances and feeling less rested in the morning predicted lower awakening cortisol and a slower cortisol decline, suggesting an association

between a dysregulation of the HPA axis and sleep dysfunction²⁰⁴.

Since sleep dysfunction is acknowledged as a remarkable criterion for the diagnosis of depression, a derivative consideration from the abovementioned data is that interventions specifically targeting sleep disturbance in cancer might have a remarkable role in reducing subsequent depressive morbidity. Multimodal approaches using sleep hygiene and education, stimulus control, sleep restriction and relaxation and cognitive-behavioral therapy emerged as the gold standard for non-pharmacologic treatment of sleep dysfunction²⁰⁵. However, further research is needed to examine the bi-directional relationships between sleep dysfunction and depression occurrence across different cancer populations. Furthermore, more studies are warranted to explore the role of sleep dysfunction in triggering pro-inflammatory alterations and influencing resilience to stress, with possible detrimental consequences for cancer outcome.

Concluding remarks

Individual suffering from cancer are at high risk of experiencing major depressive episodes throughout the trajectory of the disease, although most risk appears within the first year of diagnosis. Recent advances in the understanding of the neurobiological underpinnings of depression indicate that high levels of psychosocial stress and low social support may significantly contribute to the development of depressive symptoms in cancer populations, not only by increasing the psychological distress but also influencing biological mechanisms relevant for the pathophysiology of depression. A lower resilience to stress may translate into chronic inflammation and altered hormonal and autonomic responses, which are acknowledged factors related to the development and recurrences of depressive episodes. Likewise, stress

and depression through shared mechanisms may exert a detrimental effect on cancer-related outcomes. **Figure 1** provides a wide-angle lens of the multiple intertwined biobehavioral pathways linking stress, depression, and cancer progression. Since antidepressants might insufficiently target depression in cancer populations, the development of alternative or complementary treatment strategies is highly warranted. Behavioral interventions may be feasible adjunctive strategies for targeting depressive symptoms, cognitive dysfunction, fatigue and sleep disturbances among individuals with cancer²⁰⁶.

<Insert Figure 1 around here>

Notwithstanding, the literature in the field is typically limited by a small number of studies and heterogeneous inclusion criteria, short follow-up periods and heterogeneous assessment tools, which complicates the generalizability of results and complicates the comparison between studies, preliminary data from RCTs offered encouraging results. In addition, available literature suggests that the positive impact of behavioural strategies may be partially mediated by their anti-inflammatory potential in association with immunosurveillance-enhancing properties as well as with a modulatory impact on the activity in the HPA axis.

Prospective research may provide clearer causal inferences about the mutual interactions between cancer and depression, and inform about novel possible therapeutic options. In addition, a more profound knowledge base in this emerging field could also offer novel perspectives for the design of preventative strategies for tackling depression in cancer survivors.

FIGURE LEGEND

Fig. 1. Chronic stress may activate several intertwined biobehavioral mechanisms relevant for the development of depressive symptoms with a detrimental impact on cancer progression.

Acknowledgments

AFC is supported by a research fellowship award from the Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq; Brazil). CAK is the recipient of a postdoctoral fellowship award from the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES; Brazil).

References

1. Lutgendorf SK, Andersen BL. Biobehavioral approaches to cancer progression and survival: Mechanisms and interventions. *Am Psychol.* 2015;70:186-97.
2. Satin JR, Linden W, Phillips MJ. Depression as a predictor of disease progression and mortality in cancer patients: a meta-analysis. *Cancer.* 2009;115:5349-61.
3. Pelletier G, Verhoef MJ, Khatri N, Hagen N. Quality of life in brain tumor patients: the relative contributions of depression, fatigue, emotional distress, and existential issues. *J Neurooncol.* 2002;57:41-9.
4. Fann JR, Thomas-Rich AM, Katon WJ, Cowley D, Pepping M, McGregor BA, et al. Major depression after breast cancer: a review of epidemiology and treatment. *Gen Hosp Psychiatry.* 2008;30:112-26.
5. Faller H, Bulzebruck H, Drings P, Lang H. Coping, distress, and survival among patients with lung cancer. *Arch Gen Psychiatry.* 1999;56:756-62.
6. Tang PL, Wang HH, Chou FH. A Systematic Review and Meta-Analysis of Demoralization and Depression in Patients With Cancer. *Psychosomatics.* 2015;56:634-43.
7. Meijer A, Roseman M, Delisle VC, Milette K, Levis B, Syamchandra A, et al. Effects of screening for psychological distress on patient outcomes in cancer: a systematic review. *Journal of psychosomatic research.* 2013;75:1-17.
8. Giese-Davis J, Collie K, Rancourt KM, Neri E, Kraemer HC, Spiegel D. Decrease in depression symptoms is associated with longer survival in patients with metastatic breast cancer: a secondary analysis. *J Clin Oncol.* 2011;29:413-20.

9. Fann JR, Fan MY, Unutzer J. Improving primary care for older adults with cancer and depression. *J Gen Intern Med.* 2009;24 Suppl 2:S417-24.
10. Jehn CF, Becker B, Flath B, Nogai H, Vuong L, Schmid P, et al. Neurocognitive function, brain-derived neurotrophic factor (BDNF) and IL-6 levels in cancer patients with depression. *Journal of neuroimmunology.* 2015;287:88-92.
11. Lebera A, Vegas O, Gomez-Lazaro E, Arregi A, Garmendia L, Beitia G, et al. Melanoma tumors alter proinflammatory cytokine production and monoamine brain function, and induce depressive-like behavior in male mice. *Behavioural brain research.* 2014;272:83-92.
12. Hughes S, Jaremka LM, Alfano CM, Glaser R, Povoski SP, Lipari AM, et al. Social support predicts inflammation, pain, and depressive symptoms: longitudinal relationships among breast cancer survivors. *Psychoneuroendocrinology.* 2014;42:38-44.
13. Kurz K, Schroecksadel S, Weiss G, Fuchs D. Association between increased tryptophan degradation and depression in cancer patients. *Current opinion in clinical nutrition and metabolic care.* 2011;14:49-56.
14. Wei YC, Zhou FL, He DL, Bai JR, Ding H, Wang XY, et al. Oxidative stress in depressive patients with gastric adenocarcinoma. *The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP).* 2009;12:1089-96.
15. Cardoso G, Graca J, Klut C, Trancas B, Papoila A. Depression and anxiety symptoms following cancer diagnosis: a cross-sectional study. *Psychol Health Med.* 2015:1-9.
16. Coyne JC, Schwenk TL, Fechner-Bates S. Nondetection of depression by primary care physicians reconsidered. *Gen Hosp Psychiatry.* 1995;17:3-12.
17. Mitchell AJ, Chan M, Bhatti H, Halton M, Grassi L, Johansen C, et al. Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: a meta-analysis of 94 interview-based studies. *Lancet Oncol.* 2011;12:160-74.
18. Ahn HK, Bae JH, Ahn HY, Hwang IC. Risk of cancer among patients with depressive disorder: a meta-analysis and implications. *Psychooncology.* 2016.
19. Schag CA, Ganz PA, Polinsky ML, Fred C, Hirji K, Petersen L. Characteristics of women at risk for psychosocial distress in the year after breast cancer. *J Clin Oncol.* 1993;11:783-93.
20. Polsky D, Doshi JA, Marcus S, Oslin D, Rothbard A, Thomas N, et al. Long-term risk for depressive symptoms after a medical diagnosis. *Arch Intern Med.* 2005;165:1260-6.
21. Kangas M, Henry JL, Bryant RA. The course of psychological disorders in the 1st year after cancer diagnosis. *J Consult Clin Psychol.* 2005;73:763-8.
22. Schrepf A, Lutgendorf SK, Pyter LM. Pre-treatment effects of peripheral tumors on brain and behavior: neuroinflammatory mechanisms in humans and rodents. *Brain Behav Immun.* 2015;49:1-17.
23. Cosci F, Fava GA, Sonino N. Mood and anxiety disorders as early manifestations of medical illness: a systematic review. *Psychotherapy and psychosomatics.* 2015;84:22-9.
24. Green AI, Austin CP. Psychopathology of pancreatic cancer. A psychobiologic probe. *Psychosomatics.* 1993;34:208-21.
25. Wedding U, Koch A, Rohrig B, Pientka L, Sauer H, Hoffken K, et al. Requestioning depression in patients with cancer: contribution of somatic and affective symptoms to Beck's Depression Inventory. *Ann Oncol.* 2007;18:1875-81.

26. Vine MF, Calingaert B, Berchuck A, Schildkraut JM. Characterization of prediagnostic symptoms among primary epithelial ovarian cancer cases and controls. *Gynecol Oncol.* 2003;90:75-82.
27. Lutgendorf SK, Weinrib AZ, Penedo F, Russell D, DeGeest K, Costanzo ES, et al. Interleukin-6, cortisol, and depressive symptoms in ovarian cancer patients. *J Clin Oncol.* 2008;26:4820-7.
28. Van Esch L, Roukema JA, Ernst MF, Nieuwenhuijzen GA, De Vries J. Combined anxiety and depressive symptoms before diagnosis of breast cancer. *J Affect Disord.* 2012;136:895-901.
29. Eskelinen M, Ollonen P. Beck Depression Inventory (BDI) in patients with breast disease and breast cancer: a prospective case-control study. *In Vivo.* 2011;25:111-6.
30. Liu L, Rissling M, Natarajan L, Fiorentino L, Mills PJ, Dimsdale JE, et al. The longitudinal relationship between fatigue and sleep in breast cancer patients undergoing chemotherapy. *Sleep.* 2012;35:237-45.
31. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. *Cell.* 2011;144:646-74.
32. Reuter S, Gupta SC, Chaturvedi MM, Aggarwal BB. Oxidative stress, inflammation, and cancer: how are they linked? *Free Radic Biol Med.* 2010;49:1603-16.
33. Valpione S, Martinoli C, Fava P, Mocellin S, Campana LG, Quaglino P, et al. Personalised medicine: Development and external validation of a prognostic model for metastatic melanoma patients treated with ipilimumab. *Eur J Cancer.* 2015;51:2086-94.
34. Armaiz-Pena GN, Cole SW, Lutgendorf SK, Sood AK. Neuroendocrine influences on cancer progression. *Brain Behav Immun.* 2013;30 Suppl:S19-25.
35. Sica A, Mantovani A. Macrophage plasticity and polarization: in vivo veritas. *J Clin Invest.* 2012;122:787-95.
36. Tracey KJ. Reflex control of immunity. *Nat Rev Immunol.* 2009;9:418-28.
37. Qin L, Wu X, Block ML, Liu Y, Breese GR, Hong JS, et al. Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration. *Glia.* 2007;55:453-62.
38. Torres-Platas SG, Cruceanu C, Chen GG, Turecki G, Mechawar N. Evidence for increased microglial priming and macrophage recruitment in the dorsal anterior cingulate white matter of depressed suicides. *Brain Behav Immun.* 2014;42:50-9.
39. Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. *Nat Rev Neurosci.* 2008;9:46-56.
40. Najjar S, Pearlman DM, Alper K, Najjar A, Devinsky O. Neuroinflammation and psychiatric illness. *Journal of neuroinflammation.* 2013;10:43.
41. Miller AH, Maletic V, Raison CL. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. *Biological psychiatry.* 2009;65:732-41.
42. Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, et al. A meta-analysis of cytokines in major depression. *Biological psychiatry.* 2010;67:446-57.
43. Liu Y, Ho RC, Mak A. Interleukin (IL)-6, tumour necrosis factor alpha (TNF-alpha) and soluble interleukin-2 receptors (sIL-2R) are elevated in patients with major depressive disorder: a meta-analysis and meta-regression. *J Affect Disord.* 2012;139:230-9.
44. Valkanova V, Ebmeier KP, Allan CL. CRP, IL-6 and depression: a systematic review and meta-analysis of longitudinal studies. *J Affect Disord.* 2013;150:736-44.

45. Capuron L, Gummnick JF, Musselman DL, Lawson DH, Reemsnyder A, Nemeroff CB, et al. Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. *Neuropsychopharmacology*. 2002;26:643-52.
46. Bufalino C, Heggul N, Aguglia E, Pariante CM. The role of immune genes in the association between depression and inflammation: a review of recent clinical studies. *Brain Behav Immun*. 2013;31:31-47.
47. Haapakoski R, Ebmeier KP, Alenius H, Kivimaki M. Innate and adaptive immunity in the development of depression: An update on current knowledge and technological advances. *Progress in neuro-psychopharmacology & biological psychiatry*. 2016;66:63-72.
48. Leonard B, Maes M. Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression. *Neuroscience and biobehavioral reviews*. 2012;36:764-85.
49. Slyepchenko A, Maes M, Kohler CA, Anderson G, Quevedo J, Alves GS, et al. T helper 17 cells may drive neuroprogression in major depressive disorder: Proposal of an integrative model. *Neuroscience and biobehavioral reviews*. 2016;64:83-100.
50. Raison CL, Dantzer R, Kelley KW, Lawson MA, Woolwine BJ, Vogt G, et al. CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-alpha: relationship to CNS immune responses and depression. *Molecular psychiatry*. 2010;15:393-403.
51. Maes M, Leonard BE, Myint AM, Kubera M, Verkerk R. The new '5-HT' hypothesis of depression: cell-mediated immune activation induces indoleamine 2,3-dioxygenase, which leads to lower plasma tryptophan and an increased synthesis of detrimental tryptophan catabolites (TRYCATs), both of which contribute to the onset of depression. *Progress in neuro-psychopharmacology & biological psychiatry*. 2011;35:702-21.
52. Munn DH, Mellor AL. IDO in the Tumor Microenvironment: Inflammation, Counter-regulation, and Tolerance. *Trends Immunol*. 2016.
53. Numakawa T, Richards M, Nakajima S, Adachi N, Furuta M, Odaka H, et al. The role of brain-derived neurotrophic factor in comorbid depression: possible linkage with steroid hormones, cytokines, and nutrition. *Front Psychiatry*. 2014;5:136.
54. Fernandes BS, Molendijk ML, Kohler CA, Soares JC, Leite CM, Machado-Vieira R, et al. Peripheral brain-derived neurotrophic factor (BDNF) as a biomarker in bipolar disorder: a meta-analysis of 52 studies. *BMC Med*. 2015;13:289.
55. Sperner-Unterweger B, Kohl C, Fuchs D. Immune changes and neurotransmitters: possible interactions in depression? *Progress in neuro-psychopharmacology & biological psychiatry*. 2014;48:268-76.
56. Kohler O, Benros ME, Nordentoft M, Farkouh ME, Iyengar RL, Mors O, et al. Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: a systematic review and meta-analysis of randomized clinical trials. *JAMA Psychiatry*. 2014;71:1381-91.
57. Raison CL, Rutherford RE, Woolwine BJ, Shuo C, Schettler P, Drake DF, et al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. *JAMA Psychiatry*. 2013;70:31-41.
58. Mehta D, Raison CL, Woolwine BJ, Haroon E, Binder EB, Miller AH, et al. Transcriptional signatures related to glucose and lipid metabolism predict treatment

response to the tumor necrosis factor antagonist infliximab in patients with treatment-resistant depression. *Brain Behav Immun.* 2013;31:205-15.

59. Slyepchenko A, Brunoni AR, McIntyre RS, Quevedo J, Carvalho AF. The Adverse Effects of Smoking on Health Outcomes in Bipolar Disorder: A Review and Synthesis of Biological Mechanisms. *Curr Mol Med.* 2016;16:187-205.

60. Coelho R, Viola TW, Walss-Bass C, Brietzke E, Grassi-Oliveira R. Childhood maltreatment and inflammatory markers: a systematic review. *Acta psychiatrica Scandinavica.* 2014;129:180-92.

61. Post RM, Altshuler LL, Leverich GS, Frye MA, Suppes T, McElroy SL, et al. Role of childhood adversity in the development of medical co-morbidities associated with bipolar disorder. *J Affect Disord.* 2013;147:288-94.

62. Cohen L, Cole SW, Sood AK, Prinsloo S, Kirschbaum C, Arevalo JM, et al. Depressive symptoms and cortisol rhythmicity predict survival in patients with renal cell carcinoma: role of inflammatory signaling. *PLoS One.* 2012;7:e42324.

63. Bower JE, Ganz PA, Aziz N, Fahey JL. Fatigue and proinflammatory cytokine activity in breast cancer survivors. *Psychosom Med.* 2002;64:604-11.

64. Tookman AJ, Jones CL, DeWitte M, Lodge PJ. Fatigue in patients with advanced cancer: a pilot study of an intervention with infliximab. *Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer.* 2008;16:1131-40.

65. Jehn CF, Kuhnhardt D, Bartholomae A, Pfeiffer S, Schmid P, Possinger K, et al. Association of IL-6, hypothalamus-pituitary-adrenal axis function, and depression in patients with cancer. *Integr Cancer Ther.* 2010;9:270-5.

66. Sotelo JL, Musselman D, Nemeroff C. The biology of depression in cancer and the relationship between depression and cancer progression. *Int Rev Psychiatry.* 2014;26:16-30.

67. Volden PA, Conzen SD. The influence of glucocorticoid signaling on tumor progression. *Brain Behav Immun.* 2013;30 Suppl:S26-31.

68. Weinrib AZ, Sephton SE, Degeest K, Penedo F, Bender D, Zimmerman B, et al. Diurnal cortisol dysregulation, functional disability, and depression in women with ovarian cancer. *Cancer.* 2010;116:4410-9.

69. Schrepf A, Clevenger L, Christensen D, DeGeest K, Bender D, Ahmed A, et al. Cortisol and inflammatory processes in ovarian cancer patients following primary treatment: relationships with depression, fatigue, and disability. *Brain Behav Immun.* 2013;30 Suppl:S126-34.

70. Torres MA, Pace TW, Liu T, Felger JC, Mister D, Doho GH, et al. Predictors of depression in breast cancer patients treated with radiation: role of prior chemotherapy and nuclear factor kappa B. *Cancer.* 2013;119:1951-9.

71. Musselman DL, Lawson DH, Gumnick JF, Manatunga AK, Penna S, Goodkin RS, et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. *N Engl J Med.* 2001;344:961-6.

72. Raison CL, Borisov AS, Broadwell SD, Capuron L, Woolwine BJ, Jacobson IM, et al. Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction. *J Clin Psychiatry.* 2005;66:41-8.

73. van Heeringen K, Zivkov M. Pharmacological treatment of depression in cancer patients. A placebo-controlled study of mianserin. *Br J Psychiatry.* 1996;169:440-3.

74. Razavi D, Allilaire JF, Smith M, Salimpour A, Verra M, Desclaux B, et al. The effect of fluoxetine on anxiety and depression symptoms in cancer patients. *Acta psychiatrica Scandinavica.* 1996;94:205-10.

75. Riechelmann RP, Burman D, Tannock IF, Rodin G, Zimmermann C. Phase II trial of mirtazapine for cancer-related cachexia and anorexia. *The American journal of hospice & palliative care*. 2010;27:106-10.
76. Kast RE, Foley KF. Cancer chemotherapy and cachexia: mirtazapine and olanzapine are 5-HT₃ antagonists with good antiemetic effects. *European journal of cancer care*. 2007;16:351-4.
77. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. *The American journal of psychiatry*. 2006;163:28-40.
78. Carvalho AF, Sharma MS, Brunoni AR, Vieta E, Fava GA. The Safety, Tolerability and Risks Associated with the Use of Newer Generation Antidepressant Drugs: A Critical Review of the Literature. *Psychotherapy and psychosomatics*. 2016;85:270-88.
79. Cotterchio M, Kreiger N, Darlington G, Steingart A. Antidepressant medication use and breast cancer risk. *Am J Epidemiol*. 2000;151:951-7.
80. Sharpe CR, Collet JP, Belzile E, Hanley JA, Boivin JF. The effects of tricyclic antidepressants on breast cancer risk. *Br J Cancer*. 2002;86:92-7.
81. Harlow BL, Cramer DW, Baron JA, Titus-Ernstoff L, Greenberg ER. Psychotropic medication use and risk of epithelial ovarian cancer. *Cancer Epidemiol Biomarkers Prev*. 1998;7:697-702.
82. Dalton SO, Poulsen AH, Norgaard M, McLaughlin JK, Johansen C, Friis S. Tricyclic antidepressants and non-Hodgkin lymphoma. *Epidemiology*. 2008;19:546-9.
83. Coogan PF, Palmer JR, Strom BL, Rosenberg L. Use of selective serotonin reuptake inhibitors and the risk of breast cancer. *Am J Epidemiol*. 2005;162:835-8.
84. Bahl S, Cotterchio M, Kreiger N, Klar N. Antidepressant medication use and non-Hodgkin's lymphoma risk: no association. *Am J Epidemiol*. 2004;160:566-75.
85. Coogan PF, Strom BL, Rosenberg L. Antidepressant use and colorectal cancer risk. *Pharmacoepidemiol Drug Saf*. 2009;18:1111-4.
86. Toh S, Rodriguez LA, Hernandez-Diaz S. Use of antidepressants and risk of lung cancer. *Cancer Causes Control*. 2007;18:1055-64.
87. Frick LR, Rapanelli M. Antidepressants: influence on cancer and immunity? *Life Sci*. 2013;92:525-32.
88. Grygier B, Arteta B, Kubera M, Basta-Kaim A, Budziszewska B, Leskiewicz M, et al. Inhibitory effect of antidepressants on B16F10 melanoma tumor growth. *Pharmacol Rep*. 2013;65:672-81.
89. Kubera M, Grygier B, Wrona D, Rogoz Z, Roman A, Basta-Kaim A, et al. Stimulatory effect of antidepressant drug pretreatment on progression of B16F10 melanoma in high-active male and female C57BL/6J mice. *Journal of neuroimmunology*. 2011;240-241:34-44.
90. Kubera M, Grygier B, Arteta B, Urbanska K, Basta-Kaim A, Budziszewska B, et al. Age-dependent stimulatory effect of desipramine and fluoxetine pretreatment on metastasis formation by B16F10 melanoma in male C57BL/6 mice. *Pharmacol Rep*. 2009;61:1113-26.
91. Vendramini-Costa DB, Carvalho JE. Molecular link mechanisms between inflammation and cancer. *Curr Pharm Des*. 2012;18:3831-52.
92. Anderson G, Maes M. Oxidative/nitrosative stress and immuno-inflammatory pathways in depression: treatment implications. *Curr Pharm Des*. 2014;20:3812-47.
93. Maes M, Galecki P, Chang YS, Berk M. A review on the oxidative and nitrosative stress (O&NS) pathways in major depression and their possible contribution to the

- (neuro)degenerative processes in that illness. *Progress in neuro-psychopharmacology & biological psychiatry*. 2011;35:676-92.
94. Moylan S, Berk M, Dean OM, Samuni Y, Williams LJ, O'Neil A, et al. Oxidative & nitrosative stress in depression: why so much stress? *Neuroscience and biobehavioral reviews*. 2014;45:46-62.
95. Lucas K, Morris G, Anderson G, Maes M. The Toll-Like Receptor Radical Cycle Pathway: A New Drug Target in Immune-Related Chronic Fatigue. *CNS Neurol Disord Drug Targets*. 2015;14:838-54.
96. Giles GI. The redox regulation of thiol dependent signaling pathways in cancer. *Curr Pharm Des*. 2006;12:4427-43.
97. Gould N, Doulias PT, Tenopoulou M, Raju K, Ischiropoulos H. Regulation of protein function and signaling by reversible cysteine S-nitrosylation. *J Biol Chem*. 2013;288:26473-9.
98. Gu Z, Kaul M, Yan B, Kridel SJ, Cui J, Strongin A, et al. S-nitrosylation of matrix metalloproteinases: signaling pathway to neuronal cell death. *Science*. 2002;297:1186-90.
99. Akhtar MW, Sunico CR, Nakamura T, Lipton SA. Redox Regulation of Protein Function via Cysteine S-Nitrosylation and Its Relevance to Neurodegenerative Diseases. *Int J Cell Biol*. 2012;2012:463756.
100. Wang Y, Zhou Z, Lylek T, Tan H, Sun Y, Parkinson FE, et al. Protein cysteine S-nitrosylation inhibits vesicular uptake of neurotransmitters. *Neuroscience*. 2015;311:374-81.
101. Murillo-Carretero M, Torroglosa A, Castro C, Villalobo A, Estrada C. S-Nitrosylation of the epidermal growth factor receptor: a regulatory mechanism of receptor tyrosine kinase activity. *Free Radic Biol Med*. 2009;46:471-9.
102. Rahman MA, Senga T, Ito S, Hyodo T, Hasegawa H, Hamaguchi M. S-nitrosylation at cysteine 498 of c-Src tyrosine kinase regulates nitric oxide-mediated cell invasion. *J Biol Chem*. 2010;285:3806-14.
103. Monteiro HP, Costa PE, Reis AK, Stern A. Nitric oxide: Protein tyrosine phosphorylation and protein S-nitrosylation in cancer. *Biomed J*. 2015;38:380-8.
104. Miller GE, Chen E, Parker KJ. Psychological stress in childhood and susceptibility to the chronic diseases of aging: moving toward a model of behavioral and biological mechanisms. *Psychological bulletin*. 2011;137:959-97.
105. Pinquart M, Duberstein PR. Associations of social networks with cancer mortality: a meta-analysis. *Crit Rev Oncol Hematol*. 2010;75:122-37.
106. Chida Y, Hamer M, Wardle J, Steptoe A. Do stress-related psychosocial factors contribute to cancer incidence and survival? *Nat Clin Pract Oncol*. 2008;5:466-75.
107. Gripp S, Moeller S, Bolke E, Schmitt G, Matuschek C, Asgari S, et al. Survival prediction in terminally ill cancer patients by clinical estimates, laboratory tests, and self-rated anxiety and depression. *J Clin Oncol*. 2007;25:3313-20.
108. McEwen BS. Central effects of stress hormones in health and disease: Understanding the protective and damaging effects of stress and stress mediators. *European journal of pharmacology*. 2008;583:174-85.
109. McEwen BS, Gianaros PJ. Central role of the brain in stress and adaptation: links to socioeconomic status, health, and disease. *Annals of the New York Academy of Sciences*. 2010;1186:190-222.
110. Moylan S, Maes M, Wray NR, Berk M. The neuroprogressive nature of major depressive disorder: pathways to disease evolution and resistance, and therapeutic implications. *Molecular psychiatry*. 2013;18:595-606.

111. Bierhaus A, Wolf J, Andrassy M, Rohleder N, Humpert PM, Petrov D, et al. A mechanism converting psychosocial stress into mononuclear cell activation. *Proceedings of the National Academy of Sciences of the United States of America*. 2003;100:1920-5.
112. Pace TW, Mletzko TC, Alagbe O, Musselman DL, Nemeroff CB, Miller AH, et al. Increased stress-induced inflammatory responses in male patients with major depression and increased early life stress. *The American journal of psychiatry*. 2006;163:1630-3.
113. Shin KJ, Lee YJ, Yang YR, Park S, Suh PG, Follo MY, et al. Molecular Mechanisms Underlying Psychological Stress and Cancer. *Curr Pharm Des*. 2016;22:2389-402.
114. Nausheen B, Carr NJ, Peveler RC, Moss-Morris R, Verrill C, Robbins E, et al. Relationship between loneliness and proangiogenic cytokines in newly diagnosed tumors of colon and rectum. *Psychosom Med*. 2010;72:912-6.
115. Costanzo ES, Lutgendorf SK, Sood AK, Anderson B, Sorosky J, Lubaroff DM. Psychosocial factors and interleukin-6 among women with advanced ovarian cancer. *Cancer*. 2005;104:305-13.
116. Lutgendorf SK, DeGeest K, Dahmouh L, Farley D, Penedo F, Bender D, et al. Social isolation is associated with elevated tumor norepinephrine in ovarian carcinoma patients. *Brain Behav Immun*. 2011;25:250-5.
117. Sood AK, Armaiz-Pena GN, Halder J, Nick AM, Stone RL, Hu W, et al. Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis. *J Clin Invest*. 2010;120:1515-23.
118. Andersen BL, Farrar WB, Golden-Kretz D, Kutz LA, MacCallum R, Courtney ME, et al. Stress and immune responses after surgical treatment for regional breast cancer. *J Natl Cancer Inst*. 1998;90:30-6.
119. Varker KA, Terrell CE, Welt M, Suleiman S, Thornton L, Andersen BL, et al. Impaired natural killer cell lysis in breast cancer patients with high levels of psychological stress is associated with altered expression of killer immunoglobulin-like receptors. *J Surg Res*. 2007;139:36-44.
120. Menke A, Binder EB. Epigenetic alterations in depression and antidepressant treatment. *Dialogues Clin Neurosci*. 2014;16:395-404.
121. Cattaneo A, Macchi F, Plazzotta G, Veronica B, Bocchio-Chiavetto L, Riva MA, et al. Inflammation and neuronal plasticity: a link between childhood trauma and depression pathogenesis. *Front Cell Neurosci*. 2015;9:40.
122. Tyrka AR, Price LH, Marsit C, Walters OC, Carpenter LL. Childhood adversity and epigenetic modulation of the leukocyte glucocorticoid receptor: preliminary findings in healthy adults. *PLoS One*. 2012;7:e30148.
123. McGowan PO, Sasaki A, D'Alessio AC, Dymov S, Labonte B, Szyf M, et al. Epigenetic regulation of the glucocorticoid receptor in human brain associates with childhood abuse. *Nature neuroscience*. 2009;12:342-8.
124. Klengel T, Mehta D, Anacker C, Rex-Haffner M, Pruessner JC, Pariante CM, et al. Allele-specific FKBP5 DNA demethylation mediates gene-childhood trauma interactions. *Nature neuroscience*. 2013;16:33-41.
125. Zimmermann P, Bruckl T, Nocon A, Pfister H, Binder EB, Uhr M, et al. Interaction of FKBP5 gene variants and adverse life events in predicting depression onset: results from a 10-year prospective community study. *The American journal of psychiatry*. 2011;168:1107-16.


126. Kang HJ, Kim JM, Lee JY, Kim SY, Bae KY, Kim SW, et al. BDNF promoter methylation and suicidal behavior in depressive patients. *J Affect Disord*. 2013;151:679-85.
127. Blaze J, Scheuing L, Roth TL. Differential methylation of genes in the medial prefrontal cortex of developing and adult rats following exposure to maltreatment or nurturing care during infancy. *Dev Neurosci*. 2013;35:306-16.
128. O'Toole PW, Jeffery IB. Gut microbiota and aging. *Science*. 2015;350:1214-5.
129. Rook GA, Raison CL, Lowry CA. Microbiota, immunoregulatory old friends and psychiatric disorders. *Adv Exp Med Biol*. 2014;817:319-56.
130. Penders J, Gerhold K, Stobberingh EE, Thijs C, Zimmermann K, Lau S, et al. Establishment of the intestinal microbiota and its role for atopic dermatitis in early childhood. *The Journal of allergy and clinical immunology*. 2013;132:601-7 e8.
131. Hsiao EY, McBride SW, Hsien S, Sharon G, Hyde ER, McCue T, et al. Microbiota modulate behavioral and physiological abnormalities associated with neurodevelopmental disorders. *Cell*. 2013;155:1451-63.
132. Borre YE, Moloney RD, Clarke G, Dinan TG, Cryan JF. The impact of microbiota on brain and behavior: mechanisms & therapeutic potential. *Adv Exp Med Biol*. 2014;817:373-403.
133. Maslanik T, Tannura K, Mahaffey L, Loughridge AB, Beninson L, Ursell L, et al. Commensal bacteria and MAMPs are necessary for stress-induced increases in IL-1beta and IL-18 but not IL-6, IL-10 or MCP-1. *PLoS One*. 2012;7:e50636.
134. Miller AH, Raison CL. The role of inflammation in depression: from evolutionary imperative to modern treatment target. *Nat Rev Immunol*. 2015;16:22-34.
135. Maes M, Kubera M, Leunis JC. The gut-brain barrier in major depression: intestinal mucosal dysfunction with an increased translocation of LPS from gram negative enterobacteria (leaky gut) plays a role in the inflammatory pathophysiology of depression. *Neuro Endocrinol Lett*. 2008;29:117-24.
136. Maes M, Kubera M, Leunis JC, Berk M. Increased IgA and IgM responses against gut commensals in chronic depression: further evidence for increased bacterial translocation or leaky gut. *J Affect Disord*. 2012;141:55-62.
137. Maes M, Kubera M, Leunis JC, Berk M, Geffard M, Bosmans E. In depression, bacterial translocation may drive inflammatory responses, oxidative and nitrosative stress (O&NS), and autoimmune responses directed against O&NS-damaged neopeptides. *Acta psychiatrica Scandinavica*. 2013;127:344-54.
138. Paul B, Barnes S, Demark-Wahnefried W, Morrow C, Salvador C, Skibola C, et al. Influences of diet and the gut microbiome on epigenetic modulation in cancer and other diseases. *Clin Epigenetics*. 2015;7:112.
139. Pompei A, Cordisco L, Amaretti A, Zanoni S, Matteuzzi D, Rossi M. Folate production by bifidobacteria as a potential probiotic property. *Appl Environ Microbiol*. 2007;73:179-85.
140. Berni Canani R, Di Costanzo M, Leone L. The epigenetic effects of butyrate: potential therapeutic implications for clinical practice. *Clin Epigenetics*. 2012;4:4.
141. Zgouras D, Wachtershauser A, Frings D, Stein J. Butyrate impairs intestinal tumor cell-induced angiogenesis by inhibiting HIF-1alpha nuclear translocation. *Biochem Biophys Res Commun*. 2003;300:832-8.
142. Shenderov BA. Metabiotics: novel idea or natural development of probiotic conception. *Microb Ecol Health Dis*. 2013;24.

143. Donohoe DR, Garge N, Zhang X, Sun W, O'Connell TM, Bunger MK, et al. The microbiome and butyrate regulate energy metabolism and autophagy in the mammalian colon. *Cell Metab.* 2011;13:517-26.
144. Elinav E, Nowarski R, Thaiss CA, Hu B, Jin C, Flavell RA. Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. *Nat Rev Cancer.* 2013;13:759-71.
145. Carrer A, Wellen KE. Metabolism and epigenetics: a link cancer cells exploit. *Curr Opin Biotechnol.* 2015;34:23-9.
146. Dash S, Clarke G, Berk M, Jacka FN. The gut microbiome and diet in psychiatry: focus on depression. *Current opinion in psychiatry.* 2015;28:1-6.
147. Sarris J, Logan AC, Akbaraly TN, Amminger GP, Balanza-Martinez V, Freeman MP, et al. Nutritional medicine as mainstream in psychiatry. *The lancet Psychiatry.* 2015;2:271-4.
148. Zhang MF, Wen YS, Liu WY, Peng LF, Wu XD, Liu QW. Effectiveness of Mindfulness-based Therapy for Reducing Anxiety and Depression in Patients With Cancer: A Meta-analysis. *Medicine (Baltimore).* 2015;94:e0897-0.
149. Cohen L, Parker PA, Vence L, Savary C, Kentor D, Pettaway C, et al. Presurgical stress management improves postoperative immune function in men with prostate cancer undergoing radical prostatectomy. *Psychosom Med.* 2011;73:218-25.
150. Witek-Janusek L, Albuquerque K, Chroniak KR, Chroniak C, Durazo-Arvizu R, Mathews HL. Effect of mindfulness based stress reduction on immune function, quality of life and coping in women newly diagnosed with early stage breast cancer. *Brain Behav Immun.* 2008;22:969-81.
151. Fawzy FI, Kemeny ME, Fawzy NW, Elashoff R, Morton D, Cousins N, et al. A structured psychiatric intervention for cancer patients. II. Changes over time in immunological measures. *Arch Gen Psychiatry.* 1990;47:729-35.
152. Sephton SE, Sapolsky RM, Kraemer HC, Spiegel D. Diurnal cortisol rhythm as a predictor of breast cancer survival. *J Natl Cancer Inst.* 2000;92:994-1000.
153. Wang ZY, Liu L, Shi M, Wang L. Exploring correlations between positive psychological resources and symptoms of psychological distress among hematological cancer patients: a cross-sectional study. *Psychol Health Med.* 2015:1-12.
154. Sugimoto H, Kawashima H, Ohno E, Hayashi D, Kuwahara T, Morishima T, et al. The prognostic factors and trajectory of HRQOL in patients with pancreatic cancer who received psychiatric intervention. *J Gastroenterol Hepatol.* 2015.
155. McGregor BA, Dolan ED, Murphy KM, Sannes TS, Highland KB, Albano DL, et al. Cognitive Behavioral Stress Management for Healthy Women at Risk for Breast Cancer: a Novel Application of a Proven Intervention. *Ann Behav Med.* 2015;49:873-84.
156. Andersen BL, Yang HC, Farrar WB, Golden-Kreutz DM, Emery CF, Thornton LM, et al. Psychologic intervention improves survival for breast cancer patients: a randomized clinical trial. *Cancer.* 2008;113:3450-8.
157. Andersen BL, Thornton LM, Shapiro CL, Farrar WB, Mundy BL, Yang HC, et al. Biobehavioral, immune, and health benefits following recurrence for psychological intervention participants. *Clin Cancer Res.* 2010;16:3270-8.
158. Favier CF, Vaughan EE, De Vos WM, Akkermans AD. Molecular monitoring of succession of bacterial communities in human neonates. *Appl Environ Microbiol.* 2002;68:219-26.

159. Tayyem RF, Bawadi HA, Shehadah I, Agraib LM, Al-Awwad NJ, Heath DD, et al. Consumption of Whole Grains, Refined Cereals, and Legumes and Its Association With Colorectal Cancer Among Jordanians. *Integr Cancer Ther*. 2015.
160. Kim Y, Je Y. Dietary fibre intake and mortality from cardiovascular disease and all cancers: A meta-analysis of prospective cohort studies. *Arch Cardiovasc Dis*. 2016;109:39-54.
161. Camargo Cde Q, Mocellin MC, Pastore Silva Jde A, Fabre ME, Nunes EA, Trindade EB. Fish oil supplementation during chemotherapy increases posterior time to tumor progression in colorectal cancer. *Nutr Cancer*. 2016;68:70-6.
162. Zhang C, Yu H, Shen Y, Ni X, Shen S, Das UN. Polyunsaturated fatty acids trigger apoptosis of colon cancer cells through a mitochondrial pathway. *Arch Med Sci*. 2015;11:1081-94.
163. Piazzini G, D'Argenio G, Prossomariti A, Lembo V, Mazzone G, Candela M, et al. Eicosapentaenoic acid free fatty acid prevents and suppresses colonic neoplasia in colitis-associated colorectal cancer acting on Notch signaling and gut microbiota. *International journal of cancer*. 2014;135:2004-13.
164. Herr I, Buchler MW. Dietary constituents of broccoli and other cruciferous vegetables: implications for prevention and therapy of cancer. *Cancer Treat Rev*. 2010;36:377-83.
165. Hughes R, Cross AJ, Pollock JR, Bingham S. Dose-dependent effect of dietary meat on endogenous colonic N-nitrosation. *Carcinogenesis*. 2001;22:199-202.
166. Gao Z, Guo B, Gao R, Zhu Q, Qin H. Microbiota dysbiosis is associated with colorectal cancer. *Front Microbiol*. 2015;6:20.
167. Mageroy MH, Tieman DM, Floystad A, Taylor MG, Klee HJ. A *Solanum lycopersicum* catechol-O-methyltransferase involved in synthesis of the flavor molecule guaiacol. *Plant J*. 2012;69:1043-51.
168. Opie RS, Itsiopoulos C, Parletta N, Sanchez-Villegas A, Akbaraly TN, Ruusunen A, et al. Dietary recommendations for the prevention of depression. *Nutr Neurosci*. 2015.
169. Widmer RJ, Flammer AJ, Lerman LO, Lerman A. The Mediterranean diet, its components, and cardiovascular disease. *Am J Med*. 2015;128:229-38.
170. Garcia-Toro M, Gili M, Ibarra O, Monzon S, Vives M, Garcia-Campayo J, et al. Metabolic syndrome improvement in depression six months after prescribing simple hygienic-dietary recommendations. *BMC Res Notes*. 2014;7:339.
171. Shinn EH, Valentine A, Jethanandani A, Basen-Engquist K, Fellman B, Urbauer D, et al. Depression and Oropharynx Cancer Outcome. *Psychosom Med*. 2016;78:38-48.
172. Smith SG, Sestak I, Forster A, Partridge A, Side L, Wolf MS, et al. Factors affecting uptake and adherence to breast cancer chemoprevention: a systematic review and meta-analysis. *Ann Oncol*. 2015.
173. van Osch FH, Jochems SH, van Schooten FJ, Bryan RT, Zeegers MP. Significant Role of Lifetime Cigarette Smoking in Worsening Bladder Cancer and Upper Tract Urothelial Carcinoma Prognosis: A Meta-Analysis. *J Urol*. 2015.
174. Schoenfeld JD, Ioannidis JP. Is everything we eat associated with cancer? A systematic cookbook review. *The American journal of clinical nutrition*. 2013;97:127-34.
175. Tomlinson D, Diorio C, Beyene J, Sung L. Effect of exercise on cancer-related fatigue: a meta-analysis. *Am J Phys Med Rehabil*. 2014;93:675-86.

176. Norden DM, Bicer S, Clark Y, Jing R, Henry CJ, Wold LE, et al. Tumor growth increases neuroinflammation, fatigue and depressive-like behavior prior to alterations in muscle function. *Brain Behav Immun*. 2015;43:76-85.
177. Dieli-Conwright CM, Orozco BZ. Exercise after breast cancer treatment: current perspectives. *Breast Cancer (Dove Med Press)*. 2015;7:353-62.
178. Gokal K, Wallis D, Ahmed S, Boiangiu I, Kancherla K, Munir F. Effects of a self-managed home-based walking intervention on psychosocial health outcomes for breast cancer patients receiving chemotherapy: a randomised controlled trial. *Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer*. 2016;24:1139-66.
179. Simpson RJ, Kunz H, Agha N, Graff R. Exercise and the Regulation of Immune Functions. *Prog Mol Biol Transl Sci*. 2015;135:355-80.
180. Schmidt ME, Wiskemann J, Armbrust P, Schneeweiss A, Ulrich CM, Steindorf K. Effects of resistance exercise on fatigue and quality of life in breast cancer patients undergoing adjuvant chemotherapy: A randomized controlled trial. *International journal of cancer*. 2015;137:471-80.
181. Travier N, Velthuis MJ, Steins Bisschop CN, van den Buijs B, Monninkhof EM, Backx F, et al. Effects of an 18-week exercise programme started early during breast cancer treatment: a randomised controlled trial. *BMC Med*. 2015;13:121.
182. van Vulpen JK, Velthuis MJ, Steins Bisschop CN, Travier N, van den Buijs BJ, Backx FJ, et al. Effects of an Exercise Program in Colon Cancer Patients Undergoing Chemotherapy. *Med Sci Sports Exerc*. 2015.
183. Furzer BJ, Ackland TR, Wallman KE, Petterson AS, Gordon SM, Wright KE, et al. A randomised controlled trial comparing the effects of a 12-week supervised exercise versus usual care on outcomes in haematological cancer patients. *Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer*. 2015.
184. Livingston PM, Craike MJ, Salmon J, Courneya KS, Gaskin CJ, Fraser SF, et al. Effects of a clinician referral and exercise program for men who have completed active treatment for prostate cancer: A multicenter cluster randomized controlled trial (ENGAGE). *Cancer*. 2015;121:2646-54.
185. Chen HM, Tsai CM, Wu YC, Lin KC, Lin CC. Randomised controlled trial on the effectiveness of home-based walking exercise on anxiety, depression and cancer-related symptoms in patients with lung cancer. *Br J Cancer*. 2015;112:438-45.
186. Kampshoff CS, Chinapaw MJ, Brug J, Twisk JW, Schep G, Nijziel MR, et al. Randomized controlled trial of the effects of high intensity and low-to-moderate intensity exercise on physical fitness and fatigue in cancer survivors: results of the Resistance and Endurance exercise After ChemoTherapy (REACT) study. *BMC Med*. 2015;13:275.
187. Mizrahi D, Broderick C, Friedlander M, Ryan M, Harrison M, Pumpa K, et al. An Exercise Intervention During Chemotherapy for Women With Recurrent Ovarian Cancer: A Feasibility Study. *Int J Gynecol Cancer*. 2015;25:985-92.
188. Yagli NV, Ulger O. The effects of yoga on the quality of life and depression in elderly breast cancer patients. *Complement Ther Clin Pract*. 2015;21:7-10.
189. Rao RM, Raghuram N, Nagendra HR, Usharani MR, Gopinath KS, Diwakar RB, et al. Effects of an integrated Yoga Program on Self-reported Depression Scores in Breast Cancer Patients Undergoing Conventional Treatment: A Randomized Controlled Trial. *Indian J Palliat Care*. 2015;21:174-81.

190. Chandwani KD, Perkins G, Nagendra HR, Raghuram NV, Spelman A, Nagarathna R, et al. Randomized, controlled trial of yoga in women with breast cancer undergoing radiotherapy. *J Clin Oncol*. 2014;32:1058-65.
191. Taso CJ, Lin HS, Lin WL, Chen SM, Huang WT, Chen SW. The effect of yoga exercise on improving depression, anxiety, and fatigue in women with breast cancer: a randomized controlled trial. *J Nurs Res*. 2014;22:155-64.
192. Schmidt ME, Meynkohn A, Habermann N, Wiskemann J, Oelmann J, Hof H, et al. Resistance Exercise and Inflammation in Breast Cancer Patients Undergoing Adjuvant Radiation Therapy: Mediation Analysis From a Randomized, Controlled Intervention Trial. *Int J Radiat Oncol Biol Phys*. 2016;94:329-37.
193. Saxton JM, Scott EJ, Daley AJ, Woodroffe M, Mutrie N, Crank H, et al. Effects of an exercise and hypocaloric healthy eating intervention on indices of psychological health status, hypothalamic-pituitary-adrenal axis regulation and immune function after early-stage breast cancer: a randomised controlled trial. *Breast Cancer Res*. 2014;16:R39.
194. Schuch FB, Vancampfort D, Richards J, Rosenbaum S, Ward PB, Stubbs B. Exercise as a treatment for depression: A meta-analysis adjusting for publication bias. *Journal of psychiatric research*. 2016;77:42-51.
195. Schuch FB, Deslandes AC, Stubbs B, Gosmann NP, Silva CT, Fleck MP. Neurobiological effects of exercise on major depressive disorder: A systematic review. *Neuroscience and biobehavioral reviews*. 2016;61:1-11.
196. Savard J, Morin CM. Insomnia in the context of cancer: a review of a neglected problem. *J Clin Oncol*. 2001;19:895-908.
197. Davis MP, Goforth HW. Long-term and short-term effects of insomnia in cancer and effective interventions. *Cancer J*. 2014;20:330-44.
198. Tian J, Chen GL, Zhang HR. Sleep status of cervical cancer patients and predictors of poor sleep quality during adjuvant therapy. *Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer*. 2015;23:1401-8.
199. Berger AM, Farr L. The influence of daytime inactivity and nighttime restlessness on cancer-related fatigue. *Oncol Nurs Forum*. 1999;26:1663-71.
200. Cho HJ, Lavretsky H, Olmstead R, Levin MJ, Oxman MN, Irwin MR. Sleep disturbance and depression recurrence in community-dwelling older adults: a prospective study. *The American journal of psychiatry*. 2008;165:1543-50.
201. Irwin MR, Olmstead RE, Ganz PA, Haque R. Sleep disturbance, inflammation and depression risk in cancer survivors. *Brain Behav Immun*. 2013;30 Suppl:S58-67.
202. Meier-Ewert HK, Ridker PM, Rifai N, Regan MM, Price NJ, Dinges DF, et al. Effect of sleep loss on C-reactive protein, an inflammatory marker of cardiovascular risk. *J Am Coll Cardiol*. 2004;43:678-83.
203. Irwin MR, Wang M, Ribeiro D, Cho HJ, Olmstead R, Breen EC, et al. Sleep loss activates cellular inflammatory signaling. *Biological psychiatry*. 2008;64:538-40.
204. Tell D, Mathews HL, Janusek LW. Day-to-day dynamics of associations between sleep, napping, fatigue, and the cortisol diurnal rhythm in women diagnosed as having breast cancer. *Psychosom Med*. 2014;76:519-28.
205. Mansel JK, Carey EC. Nonpharmacologic approach to sleep disorders. *Cancer J*. 2014;20:345-51.
206. Newby TA, Graff JN, Ganzini LK, McDonagh MS. Interventions that may reduce depressive symptoms among prostate cancer patients: a systematic review and meta-analysis. *Psychooncology*. 2015;24:1686-93.



ACCEPTED MANUSCRIPT